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ABSTRACT
COMBINATION ORAL IMMUNOTHERAPY WITH IL-10 AND IL-12 EFFECTIVELY
TREATS COLON TUMORS VIA SYNERGISTIC EFFECTS ON IL-17 PRODUCING T
CELLS AND COLON EPITHELIAL BARRIER INTEGRITY
Neal Bhutiani

June 28, 2018

In this dissertation, the relationship between colon cancer and inflammation, the utility of
novel imaging modalities for diagnosis of colitis and cancer, and the therapeutic efficacy
of orally delivered, particle-based immunotherapy for the treatment of colon cancer are
evaluated.

In Chapters One and Two, multispectral optoacoustic tomography (MSOT) is
demonstrated to effectively detect colon inflammation without the use of exogenous
contrast prior to detection using conventional colonoscopy. Oral particle uptake is
demonstrated in the distal small intestine and proximal colon, confirming site-specific
delivery.
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In Chapter Three, administration of IL-10 and IL-12 containing particles is shown to act
synergistically to significantly reduce tumor burden in the setting of established colon
tumors. Cellular mechanisms deriving from effects on CD8+ T cells and T17 cells as
well as a physiologic mechanism stemming from combination therapy’s strengthening of
colon epithelial barrier integrity are described.
In Chapter Four, the lack of efficacy of orally administered anti-PD1 therapy is
demonstrated. IL-17 and γδ T cells, but not CD4+ T cells, are shown to be critical
mediators of treatment failure. The significant anti-tumor effect of combination treatment
with either anti-IL-17A or anti- γδ TCR and anti-PD1 demonstrate exciting therapeutic
targets for future clinical trials.

Finally, in Chapter Five, a clinically relevant model of colon cancer is described. This
mutationally-driven model recapitulates the clinical scenario of single adenoma
development, adenoma to carcinoma transition, carcinoma progression, and eventual
metastasis to the liver. Such a model provides an excellent platform for preclinical
evaluation of many different aspects of colon cancer.
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INTRODUCTION
COLON CANCER
EPIDEMIOLOGY, MOLECULAR AND IMMUNOLOGIC MECHANISMS, DIAGNOSIS,
AND TREATMENT
Colon cancer epidemiology
Approximately 4.5 percent of men and women in the United States will be diagnosed
with colon cancer in their lifetime.1,2 In 2018 alone, nearly 100,000 people will be
diagnosed with a new colon cancer.1 More significantly, in this same period, 50,630
people are expected die of colon cancer (including rectal cancer), making it the second
leading cause of cancer-related deaths in the United States.1,2

While the disease has been decreasing in incidence over time as a result of improved
screening leading to detection of and intervention upon pre-malignant lesions, it still
represents a clinically significant disease process that impacts a significant number of
people. Indeed, among those diagnosed with colon cancer, only about 40% are
diagnosed with local disease (e.g. that confined only to the colon).2 The remaining 60%
demonstrate evidence of disease in either the regional lymph nodes (35%) or distant
sites, particularly the liver (Figure 1).2 While 5-year survival approaches 90% for
patients with localized disease with surgery and modern chemotherapy, that number
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drops to approximately 70% for patients with disease in their regional lymph nodes and
less than 14% for patients with distant metastases (Figure 2).2

Several risk factors have been shown to increase the risk of colon cancer (Table 1).1
Behavioral risk factors include physical inactivity, obesity, a diet high in processed and/or
red meat, smoking, and moderate to heavy alcohol use. Aside from these, a family
history of colon cancer has been associated with a two- to four- fold increased risk of
developing colon cancer.3,4 This association becomes stronger with the larger the
number of first degree relatives with colon cancer and the younger the age of those
relatives at diagnosis.

Among those with a family history of colon cancer, approximately 5% have a genetic
syndrome that increases their predisposition to developing the disease.5 The two most
prominent, hereditary nonpolyposis colon cancer (HNPCC) and familial adenomatous
polyposis (FAP), represent distinct clinicopathologic entities characterized by defects in
DNA mismatch repair (MMR) machinery (MLH1, MSH2, MSH6, PMS2) and the
adenomatous polyposis coli (APC) gene, respectively.1,6 Patients with HNPCC exhibit
both a higher likelihood of developing colon cancer over the course of their lifetime
(nearly 50% by age 70) as well as a younger median age at diagnosis (45 years). 7 FAP
patients, meanwhile, manifest innumerable polyps throughout their colon by
preadolescence and have a nearly 100% risk of developing colon cancer by age 40.8
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In addition to lifestyle and genetic risk factors, medical comorbidities also significantly
modulate an individual’s risk for colon cancer. Type 2 diabetes and, more significantly,
chronic inflammatory bowel disease (IBD; i.e. ulcerative colitis, Crohn’s disease), have
both been shown to increase an individual’s risk of developing colon cancer.9-11 Indeed,
patients with IBD have between a 2 and 5-fold greater likelihood of developing colon
cancer over the course of their lifetime, particularly if diagnosed at a young age. This
association derives from the persistent chronic inflammatory processes in the colon
leading to increased cell turnover, higher mutation potential, and other elements which
will be subsequently discussed in greater detail.

Natural history
In general, the pathogenesis of colon cancer adopts two distinct paradigms depending
on whether cancer arises spontaneously or in the setting of IBD.12,13 In the former case,
colon cancer arises as a result of an accumulation of spontaneous mutations that lead to
hyperplasia, dysplasia, and eventually, development of invasive adenocarcinoma.
Disruption of the epithelial barrier and microbial invasion results in “tumor-elicited
inflammation,” which enhances tumor growth. Meanwhile, in the setting of inflammatory
bowel disease, chronic underlying colonic mucosal inflammation leads to mutations that
result in adenocarcinoma formation, with tumor development resulting in propagation of
the pro-inflammatory milieu.

The above differences are highlighted on a phenotypic and genotypic level. While
sporadic colon cancer usually demonstrates a defined adenoma to carcinoma sequence
with serial accumulation of genetic mutations in a relatively defined fashion, cancer that
3

arises in the setting of inflammatory bowel disease usually is the result of progressively
more dysplastic colon tissue with a different pattern and sequence of genetic mutations
(Figure 3).12,14-17

Further complicating matters, sporadic colon cancer comprises several distinct subsets
that behave differently on several levels. Microsatellite unstable tumors represent a
particular entity that deserves attention. These cancers, which usually arise in the
setting of silencing of the aforementioned mismatch repair gene MLH1, carry a favorable
prognosis and demonstrate different levels of neoantigen exposure and immunogenicity
than their microsatellite stable (MSS) counterparts.18-20 The distinction between these
tumor types will be subsequently discussed in greater detail and represents a critical
area of focus for novel colon cancer therapies.

Screening for colon cancer
As previously mentioned, screening efforts have played a major role in decreasing the
incidence of colon cancer in the United States. Still, these measures, which can include
colonoscopy, flexible sigmoidoscopy, or fecal occult blood test, demonstrate varying
degrees of screening efficacy, with colonoscopy (the most invasive test) demonstrating
the highest rate of polyp of dysplasia detection.1

The need for an invasive test for optimal colon cancer screening has posed several
issues for both patients and the healthcare system. Many patients dislike the discomfort
associated with colonoscopy, as it involves not only an invasive procedure but also a
4

pre-test cathartic (bowel prep) for stool evacuation.21,22 Additionally, since the test
requires the expertise of a skilled physician and nursing staff, the costs associated with
screening are not insignificant, and patients must travel to centers with all necessary
infrastructure to have their screening performed.1 For these and other reasons,
screening rates have stagnated at approximately 65-70% in the United States.

The above factors, coupled with a larger number of American adults requiring colon
cancer screening, point to the need for non-invasive, less operator-dependent
modalities. Recently, CT colonography has emerged as a potential alternative to
colonoscopy.23 However, it remains limited in its ability to detect polyps smaller than one
centimeter. New technologies or new applications of existing technologies are thus
needed as part of the effort to improve patient compliance with colon cancer screening
guidelines and facilitate early detection of pre-malignant polyps, thereby reducing the
overall burden of the disease.

Current therapy for colon cancer
While early stage colon cancer is treated effectively with surgical resection with or
without systemic chemotherapy, locally advanced and metastatic disease portends a
significantly worse prognosis.1,2 Indeed treatment of Stage 3 and Stage 4a and/or 4b of
colorectal cancer (CRC) involves multiple rounds of chemotherapy, surgery, and
possibly hepatic embolization or ablation, conferring significant morbidity.
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Current standard of care for patients with locally advanced or metastatic colon cancer
consists of 5-fluorouracil (5-FU) based chemotherapy (i.e. in combination with leucovorin
and either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)).24-27 Systemic therapy in these
patients focuses on delaying progression of disease and, if possible, reducing their
disease burden/ thus rendering patients candidates for resection.28,29 Additionally,
chemotherapy is employed in a subset of patients who undergo resection thought to be
at high risk for recurrence postoperatively. This usually consists of between 3 and 6
months of FOLFOX or an oral 5-FU analog (capecitabine) plus oxaliplatin.30 Patients
with isolated lung or liver metastases may be candidates for metastatic tumor resection,
which, in appropriately selected patients, can significantly improve survival.31-34

In patients receiving up-front chemotherapy for unresectable disease, approximately 3045% of patients respond to first-line therapy, and overall survival is approximately 20
months.26,35,36 Meanwhile, patients receiving postoperative chemotherapy exhibit
approximately 75% disease free survival at 5 years.30 Still, these chemotherapy
regimens can cause significant toxicity, particularly nausea and vomiting, neurotoxicity
(in the case of oxaliplatin), hepatotoxicity, and neutropenia, in over 60% of patients.37
Indeed, the risk of severe toxicity increases among older patients, those with
pretreatment comorbidities, and poor performance status.

In recent years, targeted therapies against VEGF and EGFR have become standard
elements of the antineoplastic armamentarium in patients with advanced colon cancer.
Anti-VEGF and Anti-EGFR agents. The former group, which includes bevacizumab and
aflibercept and targets angiogenesis and aim to decrease blood supply to the tumor, has
6

been shown to be effective either as monotherapy or in conjunction with the multiagent
chemotherapy regimens described above.38-40 However, its use significantly increases
bleeding risk among patients undergoing surgery and incidence of severe toxicity.41-43
The latter group, which blocks pro-tumorigenic signaling through the epidermal growth
factor pathway receptor, has demonstrated effect in patients with wild type RAS
oncogenes either as monotherapy or in combination with irinotecan- or, to a lesser
extent, oxaliplatin-based regimens.44,45 While these agents have a less severe side
effect profile than anti-VEGF agents, they are associated with an increase in toxicity
when added to multi-agent chemotherapy regimens.46 These statistics, together with
those presented above, highlight the importance of developing additional therapies for
treatment of advanced stage colon cancer.

The immune system in colon cancer
As with many cancers, the immune system has been shown to play a significant role in
intrinsic prevention of colon cancer. In general, this involves both innate and adaptive
immunity. Specifically, natural killer (NK) cells have been demonstrated to prevent
tumors and control their growth through recognition of activating ligands and decreased
major histocompatibility complex I expression on tumor cells.47,48 Indeed, increased NK
cell infiltration of colon tumors has been linked with improved prognosis in patients with
colon cancer.49,50 Additionally, a subset of tumor infiltrating macrophages (M1 or M1-like
macrophages) not only directly target tumor cells, but also increase major
histocompatibility complex (MHC) and costimulatory molecule expression in addition to
producing pro-inflammatory cytokines like IL-12 and TNFα, thereby augmenting both the
innate and adaptive immune responses.51
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As previously alluded to, colon tumor cells, like many other kinds of cancer, overexpress
certain antigens that allow for their recognition by the (adaptive) immune system. Many
of these antigens represent normal self-antigens that are simply overexpressed in tumor
tissue (e.g. carcinoembryonic antigen (CEA), MUC-1, and p56) or proteins that result
from mutations in genes such as Kras and p53.52,53 Prevalence of immunogenic tumor
neoantigens is further increased in microsatellite instability (MSI) high tumors, leading to
greater lymphocyte infiltration of the tumor.54,55 This phenomenon, is, to an extent,
counterbalanced by increased regulatory T cell infiltration which can blunt the anti-tumor
immune response.56 Still, the importance of tumor infiltration by cytotoxic CD8+ T cells
and memory CD8+ T cells cannot be overstated. Patients with higher proportions of
infiltrating effector and memory CD8+ T cells have been shown to have improved
prognosis across stages.57-61 Moreover, assessing these two parameters outperformed
conventional tumor-nodes-metastasis (TNM) staging in predicting recurrence in these
patients, highlighting the importance of the anti-tumor immune response in colon
cancer.62

Conversely, regardless of the mechanism by which colon cancer arises, immune
dysregulation plays a major role in survival of tumor cells, tumor evasion of anti-tumor
immune responses, and downregulation of said immune responses. CD4+ CD25+
FoxP3+ T regulatory cells exert immunosuppressive effects that blunt anti-tumor
responses through release of cytokines like TGFβ and metabolites like adenosine.56,63
Regulatory T cell accumulation in tumors appears largely mediated by transformation of
CD4+ T cells via TGFβ signaling, which can be secreted by a number of cells, including
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immature DCs (e.g. those found under circumstances of inhibited DC maturation in the
presence of VEGF).63-67

The importance of regulatory T cells to outcomes in colon cancer is highlighted by the
fact that murine models of colon cancer have demonstrated that regulatory T cell
depletion was associated with improved response to anti-tumor vaccines.68 Similarly, in
vitro depletion of regulatory T cells in peripheral blood of colorectal cancer patients
augments lymphocyte responses against tumor-associated antigens.69,70

In addition to Tregs, myeloid derived suppressor cells exert similar immunosuppressive
functions and inhibit the functions of CD8+ T cells. Their importance in promoting tumor
survival and immunoevasion has been demonstrated in mouse models, where myeloid
derived suppressor cell (MDSC) depletion resulted in improved anti-tumor response and
tumor regression.71 These cellular mechanisms of immune evasion are complemented
by the high expression of PD-L1 on the surface of colon tumor cells, which bind to PD-1
on T cells and induce anergy and apoptotic cell death.72,73

More so than in other cancer types, interleukin-17 has been shown to play a critical role
in development and progression of colon tumors in both mouse models of disease and
among patients with early stage colon cancer.61,74-76 Production of this cytokine by
several different cell types (Th17 cells, γδ T cells, natural killer T cells, and innate
lymphoid cells), appears induced by IL-23 generated by tumor associated myeloid cells
due to weakened epithelial tight junction integrity and bacterial migration.77 Subsequent
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signaling through IL-17RA on tumor cells results in signaling cascades involving
mitogen-activated protein (MAP) kinases, extracellular signal-regulated kinases (ERK),
and NF-κB, among other factors, to promote survival and proliferation of neoplastic
epithelial cells (Figure 4).77,78

Moving beyond the immune system itself, disruption of colon epithelial barrier integrity
and bacterial translocation have also been implicated in colon tumorigenesis and
progression. Regardless of the etiology of barrier disruption, the process promotes cell
turnover and generation of a host of antimicrobial peptides and pro-inflammatory
cytokines.77,79 The resulting change in the immune milieu essentially establishes a
persistent pro-inflammatory state that is exacerbated by bacterial migration and the
dysplastic transformation of epithelial cells (Figure 5).79

Immunotherapy for colon cancer
In light of the significant role of immune dysregulation in its development and
progression, the oncology community has invested significant effort in evaluating the
potential role for immunotherapy in the treatment of colon cancer. In preclinical studies,
vaccines, checkpoint inhibitors, and adoptive cell therapies have demonstrated
significant anti-tumor effect. However, as will be subsequently discussed, such
therapies have met with more limited success in clinical trials.

Beginning over 20 years ago, researchers began investigating the potential of immunebased therapies in the treatment of colon cancer. Until recently, much of these efforts
10

focused on non-specific immune stimulation in conjunction with multi-agent
chemotherapy and development of colon cancer vaccines. The former efforts have
proven effective, particular the combination of granulocyte-monocyte colony stimulating
factor (GM-CSF) with gemcitabine and FOLFOX.80-82 In a phase III clinical trial in
patients with advanced colon cancer, this regimen was shown to result in a near
doubling of response rate and a 50% increase in progression free survival compared to
treatment with FOLFOX alone.82 The efficacy of this strategy was marked by increases
in memory T cells and increases in circulating regulatory T cells.

Vaccination efforts have focused on immunization with a wide variety of agents,
including β-human chorionic gonadotropin, carcinoembryonic antigen, mutant RAS
peptides, autologous tumor cells, and antigens loaded onto dendritic cells (DCs).
Among these, the autologous tumor cell BCG vaccine (OncoVax) has demonstrated the
greatest success.83,84 Studies demonstrated that OncoVax treatment resulted in
decreased recurrence rates and improved 5-year recurrence free survival rates among
patients with stage II colon cancer. A multicenter phase III study is currently underway
for patients with stage II colon cancer comparing OncoVax plus surgery to surgery
alone.

More recently, clinical trials investigating the effect of therapy with immune checkpoint
inhibitors, particularly anti-PD1, have demonstrated a markedly different effect in
patients with colon cancer based on their microsatellite status. Indeed, patients with MSI
high tumors exhibit response rates of 40-50% with significant improvements in
progression free and overall survival. On the contrary, patients with microsatellite stable
11

tumors respond only rarely (<5% of cases).85-88 The mechanisms of anti-PD1 resistance
in MSS colon tumors remain unclear, though recently published work suggests that
TGFβ signaling as well as mutations in JAK1/2 may play a role in this process.89,90
Further preclinical studies aimed at elucidating such mechanisms and clinical trials
attempting to use combination regimens to overcome this resistance are currently
underway.
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Figures and Tables

Figure 1: Stage at diagnosis of colon cancer. Surveillance, Epidemiology, and End
Results Program. Cancer Stat Facts: Colorectal Cancer.
https://seer.cancer.gov/statfacts/html/colorect.html. Accessed 5/9/2018, 2018.
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Figure 2: Survival distribution function of patients diagnosed with colon cancer by stage
From: Colon Cancer Survival Rates With the New American Joint Committee on Cancer
Sixth Edition Staging
J Natl Cancer Inst. 2004;96(19):1420-1425. doi:10.1093/jnci/djh275
J Natl Cancer Inst | © Oxford University Press
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Figure 3: Sequence of genetic mutations in sporadic and colitis-associated colon cancer.
Kim ER, Chang DK. Colorectal cancer in inflammatory bowel disease: the risk,
pathogenesis, prevention and diagnosis. World journal of gastroenterology.
2014;20(29):9872-9881.
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Figure 4: IL-17 Signaling in normal versus neoplastic colon epithelial cells. From
Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial
products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254-258.
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Figure 5: Physiologic alterations associated with disruption of colon epithelial barrier
integrity. From Luissint AC, Parkos CA, Nusrat A. Inflammation and the Intestinal
Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal
Repair. Gastroenterology. 2016;151(4):616-632
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Table 1: Risk factors for colon cancer. Colorectal Cancer Facts and Figures 2017-2019.
Atlanta, GA: American Cancer Society;2017
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CHAPTER ONE
ON THE RELATIONSHIP BETWEEN COLITIS AND CANCER
NONINVASIVE IMAGING OF COLITIS INDUCED BY ENTEROTOXIC BACTEROIDES
FRAGILIS

Introduction
Inflammatory bowel disease (IBD) has grown increasingly prevalent over the last half
century, with an annual incidence of approximately 250–300 per 100,000 persons in
North America.1 Diagnosis usually involves a combination of factors identified in a
patient’s history and on physical examination, stool studies, and ultimately, colonoscopy
with multiple biopsies.2 Furthermore, given the increased risk of colorectal cancer in
patients

with

IBD,

current

practice

guidelines

recommend

annual

screening

colonoscopies 8–10 y after onset of disease to assess for dysplastic changes and status
of disease.3 In addition to being especially uncomfortable for patients with IBD,
colonoscopy represents an invasive procedure that carries risk from both sedation or
anesthesia and colonic perforation. To date, no noninvasive imaging modalities have

19

been developed that accurately identify early inflammatory changes in patients’ small
bowel and colon, that can be used longitudinally to monitor the status of disease, or that
detect changes concerning for malignancy.

Multispectral optoacoustic tomography (MSOT) represents a novel modality that detects
sound waves resulting from specific molecular excitation by light. Specifically, laser
stimulation of tissues results in generation and emission of ultrasound waves.
Ultrasound waves demonstrate a significantly decreased scatter compared with light
waves before reaching the detecting transducer.4 Thus, MSOT retains speed and
sensitivity while having an improved signal-to-noise ratio compared with conventional
radiographic imaging modalities (e.g., CT and MRI4-13). To date, MSOT has
demonstrated a resolution at 78.9 mm.5,7 Furthermore, it can detect changes in tissue
architecture and the presence of oxygenated and deoxygenated hemoglobin,5-10
permitting evaluation of changes in structure and vascularity, common in IBD. Recently,
MSOT instrumentation has evolved and includes the potential for combination of
detecting both optoacoustic and ultrasound signals, which increases its radiologic
capabilities. Currently, MSOT has been used to effectively image tumor xenografts5-9 as
well as several orthotopic tumor models, including pancreatic adenocarcinoma,6,7 but not
to specifically assess inflammatory or dysplastic changes in the bowel in murine models.

Colonization with enterotoxic Bacteroides fragilis (ETBF), a pathogenic variant of a
human intestinal commensal organism, has been implicated in the pathogenesis of
IBD.14,15 Indeed, wild-type C57B/6 mice inoculated with ETBF after antibiotic-mediated
depletion of intestinal flora can either initiate colitis or worsen susceptibility to colitis
induced by other means.14,15 Like colitis observed in IBD patients, the inflammation
persists over time and comprises both local and systemic components. Here, we use
20

this model of ETBF-induced colitis in C57B/6 mice to evaluate the ability of MSOT to
detect intestinal and colonic inflammation.

Methods
Mice
C57B/6 mice (Jackson Labs) were bred in accordance with University of Louisville
(UofL) Institutional Animal Care and Use Committee (IACUC) guidelines. Six- to 7-wkold mice of both genders were used for all experiments. A total of 9 mice were used for
experiments. All experiments were conducted in accordance with UofL IACUC
guidelines. Figure 1 shows an experimental schematic.
Bacteria
ETBF strain 86-5443-2-2 was cultured under anaerobic conditions on brain–heart
infusion 1 clindamycin agar plates. Plates were streaked with bacterial stock stored in
glycerol and subsequently incubated under anaerobic conditions at 37C. After 48 h,
bacteria were harvested and suspended in liquid brain–heart infusion 1 clindamycin
broth before being incubated under anaerobic conditions for another 24 h.

Induction of Colitis
To deplete enteric pathogen load and facilitate ETBF colonization, mice were
administered clindamycin (0.1 g/L) and streptomycin (5 g/L) dissolved in drinking water
for 4 d before bacterial inoculation. Approximately 1 x 108 bacteria suspended in 200 mL
of phosphate buffered saline were then administered via oral gavage into the
gastrointestinal tract of these mice. Mice that received neither antibiotics nor bacteria
were used as controls. All mice were fed casein-based, low-anthocyanin chow ad libitum
(TekLad 2920X; Envigo) and monitored closely for signs of dehydration and provided
daily with electrolyte-rich gel supplements.
21

Imaging and statistical comparison
MSOT imaging was performed as previously described.5 Briefly, mice were anesthetized
with 1.6% isoflurane inhalant delivered in 0.8 L of medical air and 0.1 L of O2, then
depilated using a combination of shaving and application of Nair with aloe (Church &
Dwight Co.), which was removed with moist gauze. Mice were subsequently placed
prone and imaged from the superior thorax to inferior pelvis with the MSOT system
InVision 256TF (iThera Medical) using wavelengths of 680, 710, 730, 740, 760, 770,
780, 800, 850, and 900 nm with 25 averages per wavelength and an acquisition time of
10 μs per frame. Accurate subject positioning within the MSOT device was ensured
using the device's image preview function. Mice were evaluated before bacterial
inoculation (untreated normal control), 2 d after bacterial inoculation, and 7 d after
bacteria inoculation. Images were reconstructed via backprojection with 75-μm
resolution. MSOT values for oxygenated and deoxygenated hemoglobin were
determined using MSOT imaging software (ViewMSOT 3.5) and compared using linear
regression (JMP software; JMP, SAS Institute Inc.). Region-of-interest analysis was
used to determine oxy- and deoxy-hemoglobin separately (6) within the colon using a
3.5-mm2 ellipse on 4 regions of the mouse colon per time point. The mean oxygenated
hemoglobin signal intensity among the 4 regions was determined and compared using a
1-way ANOVA test with Tukey honest significant difference with JMP software.
Differences were considered significant for a P value of less than 0.05.

Colonoscopy and statistical comparison
Mice were injected intraperitoneally with 0.1 mL/20 g mouse weight of a ketamine–
xylazine cocktail (87.5 mg/kg ketamine + 12.5 mg/kg xylazine). After an adequate level
of anesthesia was achieved, an 8-French pediatric cystoscope was introduced into the
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mouse anus and advanced proximally until the scope could no longer be advanced.15,16
The colonoscope was then withdrawn slowly. The Murine Endoscopic Index of Colitis
Severity was used to quantify colitis severity (Table 1). Colitis severity score was
compared among and between groups using 1-way ANOVA with Tukey honest
significant difference. Correlation between mean MSOT oxygenated and deoxygenated
hemoglobin intensity and colitis severity score for mice evaluated with both MSOT and
colonoscopy at all 3 time points was assessed using Pearson correlation. Statistical
analyses were performed using JMP software. Differences were considered significant
for a P value of less than 0.05.

Histology
After colonoscopy, mice were euthanized. The colon was resected in its entirety and
flushed twice with phosphate-buffered saline to evacuate residual stool. Colons were
then bisected, fixed in 10% neutral-buffered formalin, and embedded in paraffin.
Sections were cut at 6-μm thickness and stained using hematoxylin and eosin. Samples
were masked to the pathologist on histologic analysis by a diagnostic pathologist at the
University of Alabama, Birmingham, Department of Pathology.

Results
Mice treated with ETBF showed a mild increase in vascularity 2 d after bacterial
inoculation (Figs. 2 and 3), with an increase in mean signal intensity of oxygenated
hemoglobin compared with untreated mice (1.150 vs. 2.716 MSOT arbitrary units
compared with untreated mice; P = 0.004). These findings were more prominent 7 d
after inoculation, with increased mean signal intensity of oxygenated hemoglobin (1.150
vs. 2.716 vs. 3.422 MSOT arbitrary units for controls vs. 2 d after ETBF vs. 7 d after
ETBF, P = 0.0002) and the development of punctate lesions on the colonic surface (Fig.
23

2C). Deoxygenated hemoglobin signal obtained via MSOT remained similar in all mice
evaluated regardless of treatment or time point.

The findings on MSOT correlated well with colonoscopic findings (r = 0.82, P = 0.013).
Compared with untreated controls, mice at 2 d after ETBF inoculation demonstrated an
increased colitis score (1.5 vs. 2.5), with mild colonic blunting and slightly deformable
stool (Figs. 2D and 2E). At 7 d after ETBF inoculation, mice displayed colonic blunting,
vascular aneurysms, fibrin coats, patchy granularity, and deeply deformable stool (Fig.
2F), yielding an average colitis score of 5.5 (Figs. 2 and 3B).

Additionally, findings on MSOT and colonoscopy corresponded well with masked
histologic analysis. Mice showed evidence of increasing inflammatory cell infiltrate and
architectural distortion at both 2 and 7 d after ETBF inoculation compared with controls
(Fig. 4). A similar progression was also evident comparing mice 2 and 7 d after ETBF
inoculation. Findings were consistent across all mice in each group.

Discussion
Our findings demonstrate that MSOT findings of hypervascularity and elevated levels of
oxyhemoglobin are associated with inflammatory changes in the colon as well as
inflammatory cell infiltrate evidenced on histology; this was associated with mild
inflammatory changes on histology that were minimally detectable on colonoscopy in the
same mice.

Clinically, MSOT offers multiple advantages over all current imaging and monitoring
modalities including higher resolution without requiring exogenous contrast agents.
Because quantification of oxygenated hemoglobin correlates with vascular changes
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seen on colonoscopy and inflammatory changes seen on histology, MSOT can provide
an objective assessment tool that can be used to monitor the severity and progression.
Additionally, given that polyposis and tumor growth are associated with local neo/hypervascularization, MSOT can be used to monitor IBD patients for tumorigenesis,
with colonoscopy used only if concerning features are identified on imaging studies.

Use of MSOT for diagnosis and monitoring of IBD has the potential to significantly affect
disease prognosis. The MSOT apparatus for use in human subjects consists of a
handheld probe similar to bedside ultrasound.7,10,17,18 Improvements in depth of tissue
penetration of optoacoustic imaging beyond 1 cm have been demonstrated in humans
using the clinical MSOT system, Acuity, with up to a 5-cm depth achieved.17,18 Therefore,
MSOT could be used to provide noninvasive screening for IBD in patients at high risk for
developing the disease because of factors such as family history and ethnicity, thereby
enabling earlier detection of disease and commencement of therapy to prevent
progression. Additionally, small changes detected on MSOT that may predict clinical
worsening of disease (e.g., increased vascularity, development of small polyps) can
prompt alteration of medical therapy or more timely colonoscopy and, if necessary,
surgery to prevent clinical worsening of disease or delayed detection of malignancy and
risk of local invasion or metastasis. Conversely, intervals between invasive monitoring
with colonoscopy can be increased in patients lacking significant changes in colonic and
mesenteric vascularity and polyposis on MSOT over time. This would decrease
monitoring cost as well as procedural risks and discomfort for IBD patients.

Conclusions
MSOT represents a noninvasive diagnostic modality that effectively identifies colitis in a
murine model. Its diagnostic accuracy is at least equivalent to current standards of
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colonoscopy and tissue histology and surpasses that of conventional imaging modalities.
With improvements in deep-tissue penetration, these factors, together with MSOT’s
detection of oxygenated and deoxygenated hemoglobin as endogenous contrast agents
and correlation of signal intensity with colitis severity, would allow MSOT to serve as a
viable modality for diagnosis and monitoring of patients with IBD for both progression of
disease and development of neoplastic intestinal lesions.
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Figures and Tables

Figure 1: Experimental schematic
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Figure 2: MSOT depicts inflammatory changes in murine colitis. Wild-type C57B/6 mice
were orally inoculated with either phosphate-buffered saline alone (control) or ETBF. (A)
MSOT imaging of mice before ETBF treatment (untreated). (B and C) Images of mice 2
and 7 d, respectively, after bacterial inoculation. Arrows indicate concentrated areas of
oxyhemoglobin corresponding to colitis (B and C). Findings on MSOT were compared
with colonoscopic findings (D–F) for each group of mice. Arrow indicates area of
inflammation indicative of colitis (F).
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Figure 3: Mean MSOT signal intensity for oxyhemoglobin correlates with colitis severity
score. Region of intensity measurements acquired for MSOT images were correlated to
colitis severity score determined from colonoscopy images. (A) Mean signal intensity of
oxyhemoglobin for each group (control, 2 d after ETBF inoculation, and 7 d after ETBF
inoculation). ***P < 0.001. (B) Average colitis severity score for each group. ***P <
0.001. Error bars represent SD. (C) Correlation between mean signal intensity of
oxyhemoglobin and mean colitis severity score for the 3 mice assessed using both
MSOT and colonoscopy at all 3 time points (r = 0.82, P = 0.013). a.u. = arbitrary units.
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Figure 4: Histology findings demonstrate inflammatory changes consistent with colitis.
Hematoxylin and eosin analysis of mouse colon demonstrated no evidence of
inflammatory cell infiltrate in control mice (A and D) and progressively increasing
polymorphonuclear leukocyte infiltrate 2 d (B and E) and 7 d (C and F) after ETBF
inoculation as indicated by arrows. Histology images shown in C and F are from mouse
represented in Figure 1.
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Table 1: Murine endoscopic index of colitis severity for objective quantification of
colonoscopic findings. Changes in colon thickness, vasculature, fibrin deposition,
mucosal granularity, and stool consistence were all noted and assigned a score based
on severity. These scores were summed to yield an overall colitis severity score. Table
was modified from Becker, et al. (16).
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CHAPTER TWO
TRACKING ORAL MICROSPHERES
EVALUATING THE UPTAKE AND DISTRIBUTION OF ORALLY-ADMINISTERED
POLYLACTIC ACID PARTICLES

Introduction
In both colorectal cancer and inflammatory bowel disease, effective, orally administered
therapies represent the ideal route of drug delivery due to ease of administration and
patient preference. Particularly in the case of immunomodulatory therapies, however,
poor bioavailability and degradation by gastrointestinal enzymes prevents such
administration from being more widely utilized. Additionally, noninvasively yet
accurately imaging both gastrointestinal cancers and inflammatory bowel disease has
proven difficult due to issues with resolution and reliance on grossly detectable
differences in tissue density and vascularity.
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The development of micro- and nano-based carriers over the last twenty years
represents an exciting mechanism to overcome these obstacles. Several studies have
demonstrated the potential utility of orally administered therapeutic particles for
treatment gastrointestinal (GI) diseases.1-5 While these molecules demonstrate
mucoadhesive properties, which allow their binding to and uptake by the intestinal
mucosa before subsequent trafficking to the mesenteric lymph nodes1, it is essential to
track the biodistribution of these delivery vehicles within the gastrointestinal tract in a
longitudinal manner to progress these treatments into clinical trials.

Multispectral optoacoustic tomography (MSOT) has recently emerged as a high
resolution, non-invasive in vivo imaging modality. To date, optoacoustic imaging has
largely identified solid tumors, namely melanoma, breast cancer, and pancreatic ductal
adenocarcinoma, and various aspects of vascularity.6-12 As MSOT does not require
exposure to radiation and nephrotoxic contrast agents, it represents a significant
improvement in resolution compared to conventional imaging modalities (e.g. computed
tomography (CT), magnetic resonance imaging (MRI), ultrasound (U/S)) heightening its
appeal as a tool for diagnosis and monitoring of various pathologies. However, unlike
other solid organs, accurately imaging the gastrointestinal tract using MSOT has proven
difficult owing to the motility of the small bowel and colon in conjunction with motion
artifact introduced by murine respiration.

Our group has worked extensively with biodegradable polylactic acid particles for use in
both intravenous and oral immunotherapy delivery.1-5,13-15 Furthermore, we have
recently described high resolution imaging of the gastrointestinal tract using MSOT.16
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This study aimed to evaluate the biodistribution and longitudinally track particle uptake
through the murine GI tract in vivo after oral administration.

Methods
Orally Delivered Particles
Polylactic acid particles containing either bovine serum albumin (BSA), BSA conjugated
to AlexaFluor 680 dye, or BSA conjugated to AlexaFluor 594 dye were synthesized
using a PIN as described previously.2 Briefly, BSA (Sigma Chemical Co., St. Louis, MO)
or BSA-AF680 and PLA (Mr 24,000 and Mr 2,000; 1:1 (w/w)], Birmingham Polymers, Inc,
Birmingham, AL) were suspended in methylene chloride (Fisher Scientific, Hampton,
NH) before being quickly poured into petroleum ether (Fisher) in order to form particles.
After formation, solvent was removed by particle filtration and lyophilization overnight.
Polylactic acid particles containing BSA-AF680 were characterized using dynamic light
scattering and transmission electron microscopy. Multiple batches of particles were
constructed to compare the repeatability of particle construction. Additionally, optical
density of particles was measured using a spectrophotometer prior to drawing them into
the gavage needle as well as after the particles were expelled from the needle. As less
than 0.0001 change in OD was observed, we determined that the particles easily passed
through at 24 gauge oral gavage needle. The encapsulation efficiencies for the BSA,
BSA-AF680, or BSA-AF594 were extrapolated from the measurements of total protein
encapsulated into the particles.
Signal Assessment Ex Vivo in Tissue Phantoms
To assess the ability of MSOT to detect AF-680 containing particles (hereafter PLABSA-AF680), PLA-BSA-AF680 was added to tissue phantoms designed to simulate
optical properties of murine tissue. The tissue phantom was constructed by following
procedures: Fixed cylindrical phantoms of 2 cm diameter were prepared using a gel
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made from distilled water containing Agar (Sigma Aldrich, St. Louis, MO, USA) for
jellification (1.3% w/w) and an intralipid 20% emulsion (Sigma Aldrich, St. Louis, MO,
USA) for light diffusion (6% v/v), resulting in a gel presenting a reduced scattering
coefficient of μ's ≈ 10 cm-1. Blank PLA particles, PLA-BSA-AF60, or BSA-AF680 samples
were inserted into cylindrical inclusions approximately 3 mm diameter. The gel used to
construct the tissue phantom was used to seal the samples in the appropriate well prior
to MSOT imaging
MSOT imaging of the phantoms was done at a single position located approximately in
the middle of the phantom. Data acquisition was performed at wavelengths of 680, 710,
730, 740, 760, 770, 780, 800, 850, 900 nm, using 10 averages per wavelength resulting
in 1 s acquisition time per wavelength. Signal was measured using a Region of Interest
method from MSOT images. Data obtained in MSOT arbitrary units (a.u.) was
statistically compared using ANOVA.
Mice and particle delivery
Balb/c mice were placed on a low anthacyanin, casein-based diet for 48-72 hours prior
to particle administration. They were then orally gavaged with and equal admixture of
PLA-BSA-AF680 (10 μg AF680-BSA/1 mg particles) and PLA-BSA-AF594 (10 μg
AF594-BSA/1 mg particles) suspended in phosphate buffered saline (PBS) or an equal
admixture of naked AF680-BSA (hereafter BSA-AF680) and AF-594-BSA (hereafter
BSA-AF594) suspended in PBS. This was done to allow for particle visualization using
both MSOT and fluorescent microscopy. Mice each received a total of 5 mg of PLABSA-AF680 + 5 mg PLA-BSA-AF594 in 100 μL PBS or 50 μg BSA-AF680 + 50 μg BSAAF594 suspended in 100 μL PBS. After hair removal using Nair with aloe (Church &
Dwight Co., Inc., New Jersey, USA), mice were imaged using multispectral optoacoustic
tomography.
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Multispectral Optoacoustic Tomography
Multispectral optoacoustic tomographic (MSOT) imaging was performed as previously
described. Briefly, after anesthesia with 1.6% isofluorane, mice were prepared for
imaging using a combination of manual shaving and Nair cream with aloe (Church and
Dwight Co., Princeton, NJ, USA)17. Mice were subsequently imaged using the MSOT
system InVision TF 256 (iThera Medical, Munich, Germany) using wavelengths of 680,
710, 730, 740, 760, 770, 780, 800, 850, and 900 nm with 25 averages per wavelength
and an acquisition time of 10 µs per frame. The water temperature was 35oC within the
instrument during acquisition.

MSOT Image Reconstruction and Analysis
Raw data obtained with MSOT was reconstructed with multispectral analysis performed
as previously described 10,18. Spectral analysis was performed at wavelengths
corresponding to deoxy-hemoglobin and BSA-680. Reconstruction was conducted using
backprojection at a resolution of 75µm using ViewMSOT software version 3.5 (iThera
Medical, Munich, Germany). The Multispectral Processing was conducted using Linear
Regression with ViewMSOT 3.5, where known molar absorptivity spectra (e.g. for oxyhemoglobin, deoxy-hemoglobin, and nanoparticle) are used to model the relationship
between chromophore concentration and MSOT signal over a range of wavelengths.
The approach assumes knowledge about all absorbers present in the imaged tissue in
order to correctly attribute contributions from the different wavelengths to the unmixed
component images19,20. In order to ensure comparability among data sets, the
reconstruction parameters (field of view, speed of sound, pixel size, and the high/low
pass filters) and spectral unmixing parameters were consistently applied to all data.
Spectral unmixing was performed in the absence of correction for fluence
heterogeneities and attenuation as a function of tissue depth including spectral coloring.
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The location of organs was identified based upon vascular pattern. In addition, a region
of interest (ROI) method was applied to determine signal strength in the stomach, liver,
small bowel, colon, spleen, and mesenteric lymph nodes (MLN) of mice acquired at 1
min, 1 h, 6 h, 12 h, 24 h, and 48 h post-gavage using ViewMSOT software and reported
as MSOT a.u. The ROI was manually created with an ellipse drawing tool using the
deoxy-hemoglobin spectrally unmixed component as a guide for organ location. The ROI
area was kept constant for all image slices 3.5 mm2, thus creating a non-uniform
elliptical prism volume of interest (VOI). The mean pixel intensity per cross-section in
the VOI for the spectrally unmixed injected agent (BSA-680) was plotted as MSOT signal
vs. position to assess the particle location. The maximal ‘mean signal per cross-section’
in the volume was used as a quantitative indicator of particle trafficking. Since
optoacoustic signals using the detection geometry of this system are subject to out-ofplane contributions, this method was used to find the center of signal intensity and
minimize variability from out-of-plane artifacts. The capacity of this optoacoustic system
to deliver semi-quantitative data reflective of relative probe accumulation in vivo in
murine models using the aforementioned reconstruction and multispectral unmixing
methods was previously established.21 The MSOT a.u. values for the particle containing
BSA-680 were compared using SAS 9.3 (Cary, NC, USA).

Organ Histology and Microscopy
After imaging, mice were euthanized and abdominal organs were embedded in paraffin,
sectioned at 6 micron thickness, and stained with hematoxylin and eosin (H&E) for
evaluation using fluorescence microscopy. Images were acquired using both
conventional white light and fluorescence lamps. MSOT images were correlated with
fluorescence microscopy images to determine accuracy of MSOT based particle
localization. For an experimental schematic, please see Figure 1.
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Results
PLA particles were characterized as to size, polydispersity index, and ability to
encapsulate BSA-680. As is characteristic of the discrepancy between TEM and DLS
particle sizing, PLA particles averaged 33 nm using TEM and 46 nm using DLS (Figures
2A-B). The generation of 3 batches of PLA-BSA-680 particles also resulted in similar
sizing results along with similar polydispersity index of 0.11-0.14 (Figure 2C). Further
comparison of the spectral signature of AF-680 and BSA-680 indicated very little
spectral differences (Figure 2D). Assessment of particles in agar and intralipid tissue
phantoms demonstrated that blank PLA particles produced no signal at any excitation
wavelength (Figure 3). PLA-BSA-AF680 produced MSOT signal with intensity 32 MSOT
a.u. This was slightly less intense than but otherwise similar to the signal produced by
AF680 of 38 MSOT a.u. (Figure 3).

In in vivo studies, mice treated with PLA- BSA-AF680 exhibited MSOT signal in the
stomach at 1 min after gavage. After gavage, signal was noted in the wall of the small
bowel at starting at 1 hr after gavage up through 24 hours after gavage, in the wall of the
colon at 6, 12, and 24 h, in the MLN 12 and 24 h, and in the spleen 24 and 48h. No
signal was detected in the liver. Maximum signal post-gavage was noted in the wall of
the small bowel at 6 h, colon at 24 h, and MLN at 48 h (Figure 4). Figure 5 demonstrate
the signal noted in each respective organ at 24 hours after gavage. Intralumenal and
intraepithelial signal were differentiated through overlay of AF-680 signal on
deoxyhemoglobin signal. Mean MSOT signal intensity in target organs at each timepoint
corresponded with the visualized signal intensity (e.g. 24 hours, Figure 5).
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Compared to mice gavaged with PLA-BSA-AF680, those gavaged with BSA-AF680
demonstrated similar a much shorter duration of signal visibility on MSOT with very little
signal detected after 1 h, no signal detected after 6h, and decreased signal in target
tissues. BSA-AF680 was detected in the stomach immediately after gavage (data not
shown) and progressed through the lumen of the gastrointestinal tract over the course of
48 h, with minimal signal noted in the wall of the small bowel and colon and no signal
noted in the spleen or liver.

Particle localization on MSOT correlated well with findings on fluorescence microscopy,
which demonstrated particle localization in organs identified on MSOT at each given
timepoint (e.g. 24 hours, Figure 6). Specifically, particle uptake was visualized at the
apical aspect of epithelial cells in the small bowel and colon and in the MLNs. BSAAF680 was visualized around splenic sinusoids at the timepoints when signal was
observed on MSOT.

Discussion
Here, we describe high-resolution imaging of the murine gastrointestinal tract and
histologically correlated, site-specific uptake of poly-lactic acid particles by cells in
tissues along the gastrointestinal tract. To our knowledge, this represents the first
description of such high resolution MSOT imaging of the murine gastrointestinal tract,
specifically that which allows for tracking of orally delivered particles.

To date, high resolution gastrointestinal imaging using MSOT has proven challenging
due to a combination of 1) intrinsic gastrointestinal motility, 2) lack of fixed organ position
within the abdomen, 3) motion artifact conferred by respiration, and 4) artefactual signal
produced by anthacyanins in murine food. Ensuring an adequate level of anesthesia,
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utilizing a casein-based, low-anthacyanin diet, and, most importantly, acquiring 25
averages per wavelength proved critical to enabling detection of organ specific particle
localization in our studies. These techniques have also enabled us to image colitis in a
murine model with detection of both general areas of inflammation/hypervascularity and
individual blood vessels.16

In addition to the MSOT imaging protocol, the mucoadhesive properties of the PLA
particles facilitated organ identification and histologic correlation with MSOT imaging.
While much of the gavaged fluid-particle mixture passes through the gastrointestinal
tract, mucoadhesion enables some of the particles to be retained and taken up by
absorptive tissues. The mechanism of uptake remains unclear, but likely occurs via
phagocytosis given the size of the particles (46 nm average diameter). The importance
of mucosal adhesion is illustrated in comparing BSA-AF680 to PLA-BSA-AF680. The
former passes through the GI tract with minimal absorption, with the small amount of
absorption that occurs likely mediated by pinocytosis or passive transport with water
uptake. Meanwhile, the latter demonstrates discrete uptake and strong signal on both
MSOT (Figure 4) and histology (Figure 6).

Indeed, this correlates well with our previous findings that MSOT can reliably detect
individual nanoparticles as small as 75 nm in diameter.22 Together, the ability of MSOT
to detect such small particles as well as its ability to detect fluorophores or other
fluorescent contrast agents of various wavelengths present numerous opportunities for
clinical imaging applications within the gastrointestinal tract. Of course, use of MSOT
can avoid nephrotoxic contrast agents used in conventional imaging modalities such as
CT and MRI. However, with the ability to detect multiple fluorophores, MSOT also can
allow for particles to be administered orally and intravenously and thus enable
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simultaneous detection of inflammation, malignancy, and other pathologies.
Furthermore, varying particle size, protein or small molecule tags, and biochemical
properties (e.g. porosity and pore size, chemical composition, etc.) can allow for tissue
specific uptake based on organ or cell type (e.g. tumor cell).17,23

While MSOT accurately tracks particle uptake in the gastrointestinal tract and identifies
fluorophore signal, it does not readily distinguish between encapsulated and naked
fluorophore. For example, we observe signal of similar intensity in the colon at 24 hours
and spleen at 48 hours, but the former is produced by encapsulated fluorophore and the
latter by naked fluorophore. While this does not ostensibly impact imaging using
particle-encapsulated fluorophore, it would become important in tracking fluorophoretagged particles. In the case of PLA particles in this study, it remains unclear at which
point the particles are degraded. Discrete particles are observed in the small bowel,
colon, and MLN but not in the spleen. Degradation could be a factor of particle time in
circulation, a function of being in the lymphatic circulation, or both. Indeed, previous
studies have demonstrated the lymphatic system’s role in metabolizing elements of the
intercellular matrix and connective tissues (e.g. hyaluronan).24 Particle-specific studies
would be required to determine in vivo degradation kinetics, which would in turn impact
potential clinical applications.

The findings of this study should be viewed in light of several limitations. All imaging
was performed on Balb/c mice, as skin pigment results in signal artifact that prevents
high-resolution imaging and would have prevented particle localization. Thus, the
present of endogenous skin pigment (e.g. in the case of particularly dark-skin) would
limit clinical MSOT utility using a hand-held probe, but would likely not inhibit an
endoscopic probe in imaging such patients. Also, MSOT cannot detect non-light
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absorbing particles, so any clinical application would require incorporation of some
absorbing material (e.g. protein conjugated fluorophore, gold) within the nanoparticle.
All tissue was fixed in formalin for histology prior to H&E staining. The totality of the
processing may have resulted in the loss of some particles in target tissues at each
timepoint. Finally, the results presented herein do not necessarily reflect particle content
delivery or reflect information regarding the minimum dose of particles that results in
detectable MSOT signal in each target organ, but rather, describe the ability to monitor
particle travel in vivo using MSOT,

Despite these limitations, our findings present a number of opportunities for future
investigation. With the recently-developed clinical MSOT apparatus, nanoparticletracking studies in the gastrointestinal tract can be replicated in humans to assess the
diagnostic utility of MSOT in the clinical setting. Within the last several months,
researchers at the University of Erlangen-Nurnberg Medical School demonstrated the
ability of MSOT to detect inflammatory changes without exogenous contrast in human
subjects.25 Evaluating MSOT’s ability to track fluorophore-containing nanoparticles
represents a logical extension of this work. In examining various iterations of particles
and dyes, we would be able to correlate particle uptake with enterocolonic inflammation
as well evaluate tumor-specific uptake in the setting of enterocolonic malignancy.
Finally, using fluorophore-tagged nanoparticles, we could use MSOT to actively track
theranostic nanoparticles to actively establish pharmacokinetics of contrast and/or drug
delivery.

Conclusions
MSOT detects orally administered AF-680 dye encapsulated PLA particles in vivo.
These particles demonstrate site-specific uptake in the wall of the small bowel, colon,
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and mesenteric lymph nodes with naked dye being visible in the spleen. MSOT tracking
of fluorophore containing particles could improve monitoring of drug delivery and lead to
more optimal individualized dosing schedules. Furthermore, with improved specificity,
these particles could be further tested in humans in combination with the handheld
MSOT to help surgeons identify sites of active disease or malignancy in the operating
room.
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Figures

Figure 1: Experimental schematic for mouse experiments
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Figure 2: Characterization of the PLA-BSA-680 nanoparticles. A) Transmission electron
micrograph (TEM) images with an average particle size of 33 ± 12 nm. B) Dynamic light
scattering (DLS) of the PLA particles resulted in an average size of 44 nm. C)
Polydispersity Index (PDI) shows narrow polydispersed distribution as the PDI ranged
from 0.12-0.135 over the course of 3 batches of particles evaluated. D) Spectral
absorption was determined of AF-680 and BSA-680 which demonstrated a high degree
of similarity.
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A.

B.
Figure 3: Evaluation of optoacoustic signal within tissue phantoms of AF-680, PLA only,
and PLA-BSA-AF680. (A) MSOT signal of AF-680, particles only, and particleencapsulated AF-680 was determined using the spectral signature in Figure 2D in tissue
phantoms clearly differs from particles alone. (B) Uptake of BSA-680 within the PLA
particles was demonstrated by similarities of signal intensity between AF-680 and PLABSA-680 within tissue phantoms. Both AF-680 and PLA-BSA-680 had significantly
higher signal (p<0.05) than PLA only or empty.
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Figure 4: MSOT signal in gastrointestinal organs after oral gavage of either PLA-BSAAF680 particles or BSA-AF680 alone. (Top) MSOT imaging demonstrates nanoparticle
localization and uptake in the proximal small bowel, distal small bowel, proximal colon,
and mesenteric lymph node over the course of 48 h. (Bottom) BSA-AF680 was
undetectable after 1 h post gavage. Deoxy-hemoglobin is shown in blue and BSAAF680 in the hot color bar. All mouse images were equalized to the same intensity
scale bar.
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Figure 5: Mean MSOT signal intensity correlates with particle localization. Data shown
here reflects mean MSOT signal intensity of PLA-BSA-680 or BSA-AF680 in colon, small
bowel, and MLN 24 hours after gavage. Region of interest was determined using a 3.5
mm2 elliptical region on the assigned area of small intestine, colon, or MLN using View
MSOT 3.5. Significantly higher levels of BSA-AF680 were observed in mice that
received it via PLA particles than BSA-AF680 alone (p<0.001).
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Figure 6: Histologic visualization of PLA-BSA-AF594. (A-C) demonstrates proximal
colon 24 hours after oral gavage with PLA-BSA-AF594 (20x), with (C) showing an
overlay of particles (red) on intestinal epithelium (green). (D-F) demonstrates small
bowel 24 hours after oral gavage with particles containing AF-680 (20x), with (F) again
showing an overlay of particles (red) on intestinal epithelium (green).
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CHAPTER THREE
TREATING COLON CANCER WITH ORAL IL-10 AND IL-12: THE SYNERGY
MYSTERY
IDENTIFYING THE MECHANISMS BEHIND THE SYNERGISTIC EFFECT OF IL-10
AND IL-12 ON COLON TUMOR BURDEN AND DELINEATING THE EFFECT OF IL-10
AND IL-12 ON COLON EPITHELIAL BARRIER INTEGRITY AND ITS RELATIONSHIP
TO THE EFFICACY OF ANTINEOPLASTIC THERAPY

Introduction

The recent clinical success of immune checkpoint inhibitors (ICI) represents a major
breakthrough in cancer therapy.1 At the same time, the effectiveness of ICI has not
been uniform across different solid tumor types.2 A major cancer type that remains
highly resistant to ICI, and immune therapy in general, is mismatch repair (MMR)proficient colorectal cancer (CRC).2,3 While the mechanisms underlying resistance of
MMR-proficient CRC to immune therapy are not fully understood the need for the
development of new therapeutic approaches is clear.3
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One distinction between CRC and most other cancers is the unusual characteristics of
the tissue within which the cancer arises. The colon represents a unique environment
due to the massive commensal microbiota burden and has evolved complex
mechanisms to maintain the delicate balance between lumenal bacteria and the immune
cells that patrol the lamina propria (LP).4 Breach of the single-cell thick epithelial barrier
that separates the lumen from the LP can result in the loss of intestinal immune
homeostasis and the development of severe inflammatory pathology.5 Indeed, if such
pathology becomes chronic, it can lead to development of cancer as seen in colitisassociated cancer.6 While inflammation that results from loss of epithelial barrier
integrity can directly promote colon cancer, most sporadic CRC initially develops
independent of chronic inflammation. However, once dysplasia develops, it will result in
local compromise of the barrier and lead to what has been termed “tumor-elicited
inflammation,” a process that in turn promotes the growth of established adenomas.7
Therefore, chronic inflammation is tightly intertwined both with tumorigenesis and tumor
progression in the colon. Consistent with this paradigm, a significant body of literature
supports a major role for microbially-driven type 17 T-cell immunity (including Th17 and
γδT-cell subsets) in colon cancer.7-10 Importantly, analysis of clinical CRC samples have
revealed an inverse relationship in CD8+ cytotoxic T-lymphocyte (CTL)/Th17 cell ratio
between MMR-deficient (high CTL, low Th17) and ICI-resistant MMR-proficient (low
CTL, high Th17) tumors11 in support of the notion that the outcome of immune therapy
in CRC may be dependent on the ability to alter the CTL – Th17 cell balance.

Interleukin-10 (IL-10) is a pluripotent immune regulatory cytokine that is central to the
maintenance of immune homeostasis in mucosal tissues.12 IL-10 converts immature
blood monocytes to tolerogenic macrophages,13-15 has direct suppressive effects on
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Th17 cell activity,16 and conversely enhances conventional regulatory T-cell (cTreg)
function.17 A series of recent studies demonstrated that IL-10 directly activates antigenexperienced CD8+ cytotoxic T-lymphocytes independent of its suppressive effects on
CD4+ T-effector and/or myeloid cell subsets.18-20 Collectively, these properties have
provided the rationale for our studies evaluating the therapeutic efficacy of a novel oral
formulation of IL-10 in the treatment of intestinal polyposis21 and, more recently, of colon
cancer.22 The findings revealed that oral IL-10 could suppress tumorigenesis in the
above models via its dual activity on Th17 cells and CTL.

In this study, we tested whether oral IL-10 would be effective in eradicating established
disease either alone or in combination with IL-12, a canonical Th1 cytokine that can
directly activate tumor-associated CTL.23 The results demonstrate potent synergy
between IL-10 and IL-12, involving pleiotropic effects on immune cells and the gut
epithelium, with the latter activity being critical to overall therapeutic efficacy.

Materials and Methods

Mice and the tumor model. C57BL/6 (B6), C57BL/6J-ApcMin/J (APCMin/+) and B69SJL)IL-10ratm1.1Tlg/J (IL-10RA knockout) mice were purchased from Jackson Laboratory.
Enterotoxic B fragilis strain 86-5443-2-2 was a kind gift from Dr. Cynthia L Sears (Johns
Hopkins University School of Medicine, Baltimore, Maryland). For colonization with B
fragilis, 5-6 week old APCMin+ mice were administered clindamycin (0.1g/L) and
streptomycin (5g/L) ad libitum in drinking water for 5 days before oral gavage (~5×107
bacteria in PBS) as previously described.8 All studies were conducted in accordance
with guidelines set forth by the Institutional Animal Care and Use Committee at the
University of Louisville (Louisville, KY).
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Reagents and treatments. Two particle formulations were produced using a modified
Phase Inversion Nanoencapsulation (PIN) process:37 (i) control (no cytokine) and (ii)
recombinant murine IL-10 or IL-12-encapsulated (Peprotech, Inc.) with a loading of 0.5
μg or 0.25 μg cytokine/mg of particles, respectively. Particles were administered via oral
gavage (1 mg particles in 0.2 mL sterile water for blank, IL-10, and IL-12 treatments and
2 mL total particles in 0.2 mL sterile water for combination IL-10 and IL-12 treatment)
starting 4 weeks after B fragilis inoculation three times per week for 3 weeks. An
experimental schematic is shown in Figure 1. Administration of particles resulted in a
transient but significant increase in cytokine levels in the gut lamina propria (Figure 2).
For survival analysis, mice were treated until they reached the IACUC-approved
euthanasia score as previously described by our group.21

Gross intestinal preparation and tumor quantification. Colons were opened longitudinally
before being fixed in 10% neutral buffered formalin. Tumor burden was quantified using
a dissecting microscope.

Histology. Formalin-fixed, parrafin-embedded tissue from the distal colon was sectioned
serially (5μm sections) and subsequently stained with Hematoxylin and Eosin (H&E).
Colon histology was assessed in a blinded fashion by a single tumor pathologist. Each
section was classified as harboring no dysplasia, low grade dysplasia, or high grade
dysplasia. Colons were then scored according to the following system based on the
average severity of dysplasia in the distal colon: 0 – no dysplasia; 1 – low grade
dysplasia only; 2 – mixture of low grade and high grade dysplasia; 3 – high grade
dysplasia only; 4 – invasive cancer.
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Laser-scanning Confocal microscopy. Colon and tumor tissues were harvested from
mice, embedded in Tissue-Plus Optimal Cutting Temperature (OCT) Compound (Fisher
HealthCare, Houston, TX, USA) and snap-frozen in liquid nitrogen. Serial cryosections
(25 μm) were prepared with a Cryostar NX70, Thermo Scientific cryostat at -19 °C
(Kalamazoo, MI, USA). Cryosections were kept at room temperature for at least 24 h
prior to staining. A previously described immunostaining protocol was used with
modifications.38 For analysis of IL-10RA expression, staining antibodies were added
sequentially in the following order: IL-10RA- phycoerythrin (PE) (Novus Biologicals,
Littleton, CO), CD324 (E-Cadherin) Alexa Fluor-488 (Thermo Fisher, Waltham, MA).
Sections were washed twice with 1X PBS-T and processed for imaging. For analysis of
colon sections, staining antibodies were added sequentially in the following order: IL10RA- phycoerythrin (PE) (Novus Biologicals, Littleton, CO), CD324 (E-Cadherin) Alexa
Fluor-488 (Thermo Fisher, Waltham, MA). Antibodies were diluted with 2% fetal calf
serum (FCS) in 1X PBS pH 7.4 to 1:25 for IL-10RA-PE, and 1:25 for CD324 E-Cadherin
Alexa Fluor-488. Each antibody was sequentially incubated at 37 °C for 40 mins.
Sections were washed twice with 1X PBS-T and Prolong Gold anti-fade reagent
(Thermo Fisher, Waltham, MA) was added to the slides prior to imaging. Images were
captured using a Leica SP5 confocal laser scanning microscope (Leica, Wetzlar,
Germany) and processed using Fiji Software.39 Panels containing confocal images
were generated using Adobe Photoshop version 13.0 x32. Images were marked using
the drawing tools to highlight the results and to provide orientation of the tissues.

Colon epithelial cell isolation. Mouse (C57BL/6) colons were excised, flushed with PBS
+ penicillin and streptomycin (P/S), hemisected longitudinally, and rinsed with ice cold
PBS + P/S. Colons were then cut into 5 mm pieces and placed in a 50 mL conical tube
containing 20 mL HBSS + 1 mM DTT + 1 mM EDTA + 5% FBS. Tubes were placed in a
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hybridization oven and incubated at 200 RPM, 37°C for 40 minutes. Contents were then
passed through a 100 μm filter and centrifuged at 1500 RPM for 5 minutes. Supernatant
was discarded, and the pellet was subjected to density dependent centrifugation using a
25%/40% Percoll gradient. Cells were harvested at the interface of the solutions and
placed in 2 mL 100% FBS. Cells were centrifuged again at 1500 RPM for 5 minutes and
reconstituted in 2 mL PBS + 0.1% BSA for FACS analysis.

Flow cytometry. Membrane and intracellular staining of MLN or epithelial cells were
performed as described.22 The following antibodies were used: CD4 (GK1.5,
BioLegend), CD8α (53-6.7, BD Biosciences), CD16/CD32 (93, BioLegend), IL-17A
(TC11-18H10.1, BioLegend), RORγt (Q31-378, BD Biosciences), IFNγ (XMG1.2, BD
Biosciences), IL-10RA (1B1.3a, BioLegend), and Ep-CAM (G8.8, BioLegend).

Lymphocyte depletion and functional blockade studies. Anti-mouse CD8α (53-6.72,
BioXCell) was given intraperitoneally (ip) to APCmin/+ mice (0.2mg, three times per week
for 3 weeks) to deplete CD8+ T lymphocytes. Anti-mouse IFNγ (XMG1.2, BioXCell) was
injected ip (0.2mg, three times per week for 3 weeks). All treatments were initiated on
treatment day -1 (the day before receiving their first oral immunotherapy treatment) and
again on treatment day 0 (the day of their first oral immunotherapy treatment). Mice
were subsequently treated IP twice weekly for the duration of their 3 week oral
immunotherapy treatment regimen.

Colon permeability study. Colon permeability was assessed using a FITC-dextran assay
as previously described.40 Briefly, APCmin/+ / B fragilis mice were treated with oral
immunotherapy as described above. After 3 weeks of treatment, they were water
starved overnight before being gavaged with 44 mg/100 g body weight of FITC labeled
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dextran (FD4, Millipore Sigma, St. Louis, Missouri, USA) suspended in sterile PBS at a
concentration of 100 mg/mL. After a period of 4 hours, 300 mL of blood was extracted
retro-orbitally and placed in a BD SST collection tube (BD, Franklin Lakes, New Jersey,
USA). After centrifugation, serum was aspirated and diluted 1:1 with sterile PBS.
Samples were pipetted into a 96-well plate and analyzed using a plate reader (em: 485
nm, ex: 526 nm). Concentration of FITC-dextran was calculated based upon a standard
curve.

Colon explant culture. Colon tissue pieces (0.5-1 cm length) from APCmin+ / B fragilis
mice were cultured in triplicates for 24 hours in complete DMEM-high glucose medium
(supplemented with 10% fetal bovine serum, 1X penicillin-streptomycin solution) in a
humidified atmosphere (37°C, 5% CO2) in the presence of recombinant murine IL-10 (30
ng/mL, PeproTech, Rocky Hill, New Jersey, USA), recombinant murine IFNγ (20 ng/mL,
PeproTech, Rocky Hill, New Jersey, USA), or a combination of recombinant murine IL10 and IFNγ. The tissues were processed for protein preparation (tissue lysates with
RIPA buffer) using a sonic dismembrator (Model 550, Fisher Scientific). These tissue
lysates were used to determine the expression of IL-10RA, claudin-4, and occludin.

Western blots. Total protein lysates were collected either from colon tissue or colon
epithelial cells as described above using radioimmunoprecipitation assay (RIPA) buffer
(Millipore Sigma, St. Louis, Missouri, USA) and quantified using BCA protein
quantification kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA) per
instructional manual. Total protein (20-50 μg) of was resolved on Mini-PROTEAN TGX
4-20% gels (Bio-Rad, Hercules, California, USA) and transferred to polyvinylidene
difluoride membrane (0.22 μm pore; Novex, Carlsbad, California, USA). After blocking
with 3% (w/v) bovine serum albumin (BSA) (containing 1X TBS) for 1 h, the membrane
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was then incubated with HRP-conjugated anti-claudin-4, anti-occludin, anti-IL-10RA and
anti-β-actin antibodies (1:500, 1:500, 1:300 and 1:20,000 dilution, respectively) at 4 °C
overnight. For all proteins, chemiluminescent substrate (SuperSignalTM West Femto
Maximum Sensitivity Substrate, Thermo Scientific, Rockford, Illinois, USA) was used to
detect the protein bands (ImageQuant LAS 4000). Densitometry analysis of bands was
done using ImageJ software. Antibodies for claudin-4, occludin and β-actin were
purchased from Santa Cruz Biotechnologies (USA). The antibody for IL-10RA was
purchased from Novus Biologicals (USA).

Quantitative PCR. Steady-state mRNA levels in colon tissue were detected with SYBR
Green PCR Master Mix (Applied Biosystems) using the Mx3000p qPCR system (Agilent
Technologies). Results were normalized to β-actin expression. The expression level was
scaled using the 2−ΔΔCT method, with the average levels obtained for colons of APCmin/+ /
B fragilis mice treated with blank (control) microparticles set arbitrarily to 1. Primer
sequences utilized were: β-actin forward 5’-TCACCCACACTGGCCCATCTACGA-3’,
reverse 5’-TGGTGAAGCTGTAGCCACGCT-3’; IL-10RA forward 5’GCCAAGCCCTTCCTATGTGT-3’, reverse 5’-CCAGGGTGAACGTTGTGAGA-3’; IFNγ
forward 5’-GGCACAGTCATTGAAAGC-3’, reverse 5’-TGCCAGTTCCTCCAGATA-3’;
claudin-4 forward 5’-ATGGCGTCTATGGGACTACA-3’, reverse 3’TTACACATAGTTGCTGGCGG-5’; occludin forward 5’- CCTCCAATGGCAAAGTGAAT3’, reverse 3’- CTCCCCACCTGTCGTGTAGT-5’.

Statistical Analysis. Two-tailed student’s t-test was used to determine the significance of
the differences between control and experimental groups in pairwise comparisons. In
experiments with multiple groups homogeneity of inter-group variance was analyzed by
one-way ANOVA with Tukey’s honest standard difference for multiple comparisons.
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Log-rank test was utilized for analysis of survival studies. P values of 0.05 or less were
considered statistically significant. Statistical analyses were performed using GraphPad
Prism 7 (GraphPad Software, La Jolla, California, USA) and MedCalc version 17.9.7
(MedCalc Software, Ostend, Belgium).

Results

Previous studies demonstrated that oral administration of a slow-release biodegradable
particulate formulation of IL-10 suppressed intestinal polyposis in APCmin/+ mice and
early tumorigenesis the APCmin/+ / B fragilis compound colon cancer model.21, 22 We
wanted to determine whether this approach would be effective in the treatment of
established disease. To this end, APCmin/+ mice were inoculated with B fragilis and were
allowed to develop tumors prior to the initiation of therapy. They were then administered
IL-10 for 3 weeks, and colon tumor burden as well as histology were analyzed. The
results demonstrate that short-term treatment reduced tumor burden by 50% (Figure 3A)
coupled with a modest decrease in maximum tumor diameter (Figure 3B). In contrast,
treatment did not affect tumor histopathology (Figure 3C).

IL-10 suppresses colon tumorigenesis via its ability to reduce the prevalence of IL-17producing T-cells and concurrently enhance of CTL cytotoxicity.22 We therefore
hypothesized that adding IL-12 to the treatment regimen could further augment the
functional balance in favor of CTL. To test this notion, mice with established disease
were treated with each cytokine separately or the two cytokines in combination.
Analysis of tumor burden in mice that received monotherapy confirmed the beneficial
activity of IL-10 while IL-12 was found to increase average tumor number by
approximately 30% (Figure 4A). In contrast, combined therapy achieved near-complete
58

tumor elimination in the majority of mice (Figure 4A). A similar trend was observed with
regard to tumor size where combination therapy mediated a significant 30% reduction in
maximum tumor diameter. Importantly, and in contrast to treatment with IL-10 alone,
histological analysis revealed a dramatic improvement in the pathological score of
tumors in mice that received combination therapy (Fig 4B).

The above findings suggested that combined therapy not only arrested tumor growth but
actively promoted eradication of established disease. To determine whether combined
therapy could provide long-term benefit in this aggressive carcinoma model, mice with
established tumors were treated continuously with IL-10 and IL-12 in a survival study.
The data shown in Fig 4C demonstrate a 30% increase in median survival in the
treatment (93 days) vs the control (71 days) group. Importantly, approximately 30% of
the experimental mice remained alive up to and beyond 140 days post-initiation of
treatment (210 days of age), exceeding the maximum lifespan of the APCmin/+ mouse.21

Next, we wanted to delineate the cellular mechanism(s) that were responsible for the
synergy. Quantitative as well as qualitative analysis of MLN T-cell populations were
performed in control vs. treatment groups. Analysis of the IL-10 alone group
demonstrated a 35% reduction in the number of CD4+RORγt+IL-17+ Th17 cells with no
significant impact on CD8+ T-cell activity (Figure 5A). IL-12 monotherapy did not have a
detectable effect on Th17 cell numbers but enhanced CTL prevalence and activity.
Importantly, combination therapy reduced Th17 cell numbers and increased CTL activity,
enhancing the CTL to Th17 cell ratio (Figure 5A). These data demonstrate that each
cytokine modulated distinct effector mechanisms in gut-associated immune structures
with minimal cross-antagonism.
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To determine whether the observed synergy between IL-10 and IL-12 was simply due to
enhanced CTL activity in the presence of reduced Th17 prevalence, combination
treatment was performed in the presence or absence of CD8+ T-cell depletion. Analysis
of tumor burden revealed that depletion of CD8+ T-cells indeed resulted in reduced
antitumor efficacy, though this loss was partial and did not reach statistical significance
(Figure 5B). This finding, in combination with the independent observation that IL-12
alone actually worsened disease burden, suggested additional mechanisms
underpinning the observed synergy.

IL-12 mediates its immunological activity primarily via its immediate downstream effector
IFNγ.23 To obtain further insight into the dichotomous effects of IL-12 in our model, we
first investigated the requirement for IFNγ in the pro- vs anti-tumorigenic activity of IL-12
when administered alone or in combination with IL-10, respectively. In vivo
neutralization of IFNγ in the control and experimental groups demonstrated that
blockade of IFNγ activity resulted in the abrogation of both the detrimental and the
beneficial activities of IL-12, confirming that both pathways required IFNγ signaling
(Figure 6A). This finding suggested that in the combination therapy setting, cooperation
between IFNγ and IL-10, two cytokines that are traditionally thought to be antagonistic,
was responsible for the unexpected synergy.

In addition to their direct effects on immune effectors, IL-10 and IFNγ are known to
reciprocally modulate the paracellular physiology of gut epithelium,24 with potential
impact on pro-tumorigenic inflammatory processes. Specifically, in the APCmin+/- model,
modulation of gut permeability by DSS25 results in exacerbation of inflammatory activity
and promotes tumorigenesis in the colon.26 Therefore, to determine whether the IL-10and/or IL-12-IFNγ-epithelial barrier axis played a role in the observed synergy, we
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undertook examination of gut epithelial barrier function in different treatment groups.
Mice were fed FITC-labeled dextran particles, and serum levels of particles were
determined to assess gut permeability in each group. The data show that IL-10 slightly
reduced whereas IL-12 substantially enhanced (by 3-fold) permeability compared to that
in control mice (Figure 6B). In contrast, co-administration of IL-10 with IL-12 restored
serum FITC-dextran levels to steady-state, providing direct evidence that combination
therapy had significant impact not only on immune cells but also on the integrity of the
gut epithelium. Importantly, neutralization of IFNγ during treatment abrogated the
detrimental effect of IL-12 on barrier integrity, mechanistically linking the effects of the IL12-IFNγ axis on barrier integrity and tumor progression (Figure 6, panels A and C).

We next addressed the mechanism underlying the ability of IL-10 to restore epithelial
barrier function in IL-12-treated mice. IL-10 is known to enhance tight junction protein
expression in the gut epithelium.24,27-29 Separately, IFNγ was recently shown to induce
IL-10RA expression on intestinal epithelial cells.30

We therefore hypothesized that

sensitization of colon epithelium to IL-10 by the IFNγ-IL-10RA axis could be responsible
for restoration of barrier integrity in mice receiving dual therapy. To this end, we first
determined whether oral IL-12 altered IL-10RA expression in the gut. Quantitative PCR
analysis revealed that IL-12 promoted 3- and 6-fold increases in IFNγ and IL-10RA
mRNA expression in the colon, respectively; whereas IL-10 alone had no significant
effect (Figure 7A). To determine whether IL-10RA was upregulated on the colon
epithelium, we analyzed colon tissue from control and experimental groups by confocal
microscopy. The data showed robust IL-10RA expression in the colon epithelium in
mice treated with IL-12 or IL-12 + IL-10, whereas no significant protein could be
visualized in the control or IL-10 only groups (Figure 7B). We then quantitatively
assessed IL-10RA expression on colonic epithelial cells of control vs experimental mice
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by FACS analysis. These data revealed an approximately 3-fold increase in IL-10RA+
epithelial cells in the colons of mice that received IL-12 particles (Figure 7C).
Collectively, these results supported the hypothesis that restoration of barrier integrity in
mice receiving dual treatment vs IL-12 alone was associated with increased
responsiveness of IFNγ-conditioned epithelium to exogenous IL-10.

We further pursued the above hypothesis using an in vitro colon explant culture system
in which the predicted mechanism could be assessed directly. Specifically, we
evaluated the effect of cytokine exposure on select tight junction protein levels. To this
end, colons of B fragilis-infected APCmin/+ mice were incubated in media or media with IL10, IFNγ or IL-10 + IFNγ; and epithelial occludin, claudin-4 and IL-10RA expression were
quantified by qPCR and Western blot. The results demonstrated that IFNγ, alone or in
combination with IL-10, enhanced IL-10RA transcript levels by 8 to 10-fold on average
(Figure 8A). Similar increases in both occludin and claudin-4 mRNA were also
observed, but only in the combination group (Figure 6A). Western blot analysis revealed
a similar trend in protein expression in explants that were exposed to IFNγ + IL-10 for all
markers (Figure 8B). Collectively, these findings further supported the mechanistic
hypothesis that the stromal effect of the cytokines was associated with enhanced tight
junction integrity, which required IFNγ-dependent sensitization of the epithelium to IL-10
(Figure 9).

Discussion

Herein, we demonstrate that oral delivery of IL-10 and IL-12 can effectively eradicate
established tumors in the APCmin/+ / B fragilis colon cancer model. Further, we provide
mechanistic insight into the mechanisms that underlie the synergy between IL-10 and IL62

12, two conventionally-antagonistic cytokines. Specifically, we found that, in addition to
their distinct immunological effects on Th17 and CTL activity, combined administration of
IL-12 and IL-10 improved gut barrier integrity via the IFNγ-IL-10RA axis, greatly
enhancing therapeutic outcome. These findings have important clinical implications for
immune-based therapy of colon cancer, which has traditionally been resistant to this
modality.

The primary immunological effects of IL-10 and IL-12 involved distinct activities on Th17
and CD8+ T-cell activity, respectively. Specifically, IL-10 diminished the prevalence of
IL-17-producing CD4+ RORγt+ Th17 cells consistent with our previous observations.21,22
IL-12, on the other hand, enhanced IFNγ-producing CD8+ T-cell numbers. Importantly,
these activities were independent and were not antagonistic. We hypothesize that the
lack of antagonism between the two cytokines was associated with the distinct and in
some cases opposing effects of IL-10 on T-cells of different ontogeny and maturation
stage. Specifically, while IL-10 is known to globally suppress T-effector cell priming via
its tolerogenic activity on antigen-presenting cells,12-15 recent data are consistent with
differential effects on antigen-experienced effector subsets. For example, while IL-10
can directly suppress Th17 effector cell expansion,16 multiple reports have confirmed its
ability to enhance the activity of primed CD8+ T-cells.18-20,22 Conversely, the
suppression of IL-10 production by IFNγ, the downstream effector of IL-12, occurs at the
level of transcription,31 and delivery of recombinant IL-10 would bypass such a
mechanism. It is therefore likely that these selective effects on terminally-differentiated
T-effector cell subsets underlie the lack of immunological antagonism between the two
cytokines in our system.
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An unexpected finding in this study was that the sensitization of the gut epithelium to IL10 by IL-12 was ultimately responsible for the greater part of the synergistic antitumor
effect. Whereas our data demonstrate a link between barrier function and therapeutic
outcome, they do not directly address the mechanistic basis of how loss of barrier
integrity led to increased tumor growth. It is well-known that disruption of gut epithelial
barrier can promote tumor growth via complex multi-pathway inflammatory processes
that involve both microbial as well as non-microbial factors.32,33 Specifically, both type
17 and type 1 T-cell activity, as well as innate inflammatory cells can contribute to tumor
growth in the inflamed gut.32,33 In the case of the APCmin/+ / B fragilis model, microbiallydriven type 17 immunity has been shown to be essential to tumor development.8,22,34
While our findings are consistent with this paradigm, the ability of IL-12 to exacerbate
disease without significant impact on Th17 cells suggests that additional, yet
unidentified, factors that are associated with increased gut permeability may also
contribute to tumor pathogenesis in this model.

Our data provide partial insight into the molecular mechanism(s) that underlie the
combined effects of IL-12 and IL-10 on barrier function. Consistent with previous
reports, IL-12, through its downstream effector IFNγ, upregulated IL-10RA expression in
the colon epithelium in vivo and in vitro. Importantly, combined treatment of colon
explants with IFNγ + IL-10 induced the expression of tight junction proteins occludin and
claudin-4. Collectively, these observations support the hypothesis that increased IL-10
signaling in the IFNγ-conditioned gut epithelium ultimately restored barrier integrity via
enhanced tight junction formation. In this study, we examined only two tight junction
proteins that are known to be critical to barrier function. Given the variety and the
complexity of tight junction protein family, a more detailed analysis of the global changes
in tight junction protein levels as well as spatial localization could further delineate the
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molecular pathways underlying the observed effect. A question that remains is how IL10 signaling overcame the detrimental activity of IFNγ in the combination therapy group.
IL-10 and IFNγ can cross-modulate each other’s signaling pathways.30,35 Whether the
dominance of one over the other is determined simply via the relative strength of STAT1
vs STAT3 signaling, and/or through additional pathways remains to be determined.

The above findings demonstrate that colon physiology can be effectively modulated by
orally-administered slow-release cytokine formulations, establishing further proof-ofprinciple for the clinical potential of this therapy. This strategy provides the advantages
that drugs can be delivered in a tissue-specific manner to achieve sustained
physiological levels in the disease microenvironment with minimal systemic toxicity. We
have, in the past, demonstrated similar success with oral cytokine formulations in
models of IBD, intestinal polyposis and colon cancer.21,22,36 The current data not only
confirm and extend previous findings but also further identify a novel therapeutic
modality involving the synergistic use of two traditionally antagonistic cytokines.
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Figures

Figure 1: Experimental schematic

66

Figure 2: Oral delivery of cytokines to gut lamina propria. Mice (C57BL/6) were
administered a single dose of IL-10 and IL-12 particles (10 mg of each). Distal small
bowel, cecum, and proximal colon were harvested prior to particle administration (time 0)
as well as 6, 12, and 24 hours after particle administration. Tissues were flushed with
ice cold PBS + P/S and placed in 1 mL 2x cell lysis buffer (Cell Signaling Technology,
Danvers, MA) containing 1 mM PMSF and were homogenized using a disposable
Biomasher II Closed System Microtissue homogenizer (Kimble Chase Life Science,
Rockwood, TN) followed by sonication (Model 550, Fisher Scientific) for 20 seconds.
Homogenates were then incubated on ice for 20 minutes, centrifuged for 20 minutes at
12,000 x g and supernatants were analyzed for IL-10 and IL-12 by enzyme-linked
immunosorbent assay (ELISA) using the LegendMax mouse IL-10 and mouse IL-12p70
ELISA kits (BioLegend, San Diego, CA). Error bars = SD, n = 5 mice/time point.
Statistical significance: ** and *** denote p < 0.01 and 0.001, respectively.
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Figure 3: Oral IL-10 reduces tumor burden in mice with established disease. (A, B)
Colon tumor number and maximum diameter. APCmin/+ mice were treated with oral
particle-based therapy (either blank particles or particles loaded with recombinant
murine IL-10) for 3 weeks beginning 4 weeks after enterotoxic B fragilis inoculation.
Mice were then euthanized, and tumor number (A) and maximum tumor diameter (B) in
the mouse colon were assessed. Error bars = SD, n = 5 per group. (C, D) Histologic
severity of disease. At the time of euthanasia, colons were fixed in 10% neutral buffered
formalin, embedded in paraffin, and stained with hematoxylin and eosin as described in
Methods and Materials (C). Colons were serially sectioned and degree of dysplasia
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classified according to the following scale: no dysplasia (0), low grade dysplasia (1), mix
of low and high grade dysplasia (2), high grade dysplasia (3) and invasive cancer (4).
Examples of no dysplasia (a); low grade dysplasia with pseudo-stratification of the nuclei
and nuclear enlargement (b); cribriforming tumor glands significant for high grade
dysplasia (c); and surface epithelium with higher grade tumor underneath significant for
invasion (d) are shown. Magnification: 20X (D). Error bars = SD. n = 3 per group.
Significance: *, **, *** denote p<0.05, 0.01, 0.001, respectively.
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Figure 4: Oral IL-10 and IL-12 act synergistically to eradicate established disease and
improve overall survival. (A, B) Colon tumor number and maximum diameter. APCmin/+ /
B fragilis mice were treated with oral particle-based therapy (blank, IL-10, IL-12, or a
mixture of IL-10 and IL-12 particles) as in Figure 1. Mice were then euthanized, and
tumor number (A) and maximum tumor diameter (B) in the mouse colon were assessed.
Error bars = SD, n = 7-8 per group. (C) Histologic severity of disease. At the time of
euthanasia, colons were fixed and H&E-stained sections were analyzed as in Figure 1.
Error bars = SD, n = 3 per group. (D) Overall survival. APCmin/+ / B fragilis mice were
treated until euthanasia. n = 12 and 10 for control and experimental groups,
respectively. Significance: *, **, *** denote p<0.05, 0.01, 0.001, respectively.
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Figure 5: Distinct immunological effects of IL-10 and IL-12 on T-cell subsets are partially
responsible for the antitumor synergy. (A) Effect of orally administered IL-10 and IL-12
on Th17 and CD8+ T cells. APCmin/+ / B fragilis mice were treated with oral particlebased therapy (blank, IL-10, IL-12, or a mixture of IL-10 and IL-12 particles) as in Figure
1. Mice were euthanized and lymphocytes were isolated from mesenteric lymph nodes.
CD45+CD4+RORγt+ cells were gated on and analyzed for IL-17 production (Th17), and
CD45+CD8+ T cells were analyzed for IFNγ production (CD8+ T-cells) by FACS. Cell
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numbers shown are per MLN. For CD8+ T-cell panel: filled-in circles = % of total
lymphocytes; box plot = number of CD8+ IFNγ+ cells. Boxes have lines at the median
plus lower and upper quartiles, with whiskers extending to show the remaining data.
Error bars = SD, n=5 per group. (B) Effect of CD8+ T cell depletion on tumor burden.
Tumor-bearing APCmin/+ mice were treated as in Figure 2 in the absence or presence of
anti-CD8α monoclonal antibody administration and assessed for tumor burden. Error
bars = SD, n = 5-6 per group. Significance: *, ** denote p<0.05, 0.01, respectively.
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Figure 6: Therapeutic synergy requires IFNγ and is in part associated with the effects of
cytokines on gut epithelial barrier integrity. (A) Effect of IFNγ neutralization on
therapeutic outcome. Tumor-bearing APCmin/+ mice were treated as in Figure 2 in the
absence or presence of anti-IFNγ monoclonal antibody administration and assessed for
tumor burden. (B) Gut permeability. Experimental mice were administered FITC-labeled
dextran via oral gavage at the end of treatment and sera were analyzed for fluorescence
to assess leakage as described in Methods and Materials. (C) Effect of IFNγ
neutralization on gut permeability. Mice were treated in the absence or presence of
IFNγ-neutralizing antibody and sera were analyzed as above. Naïve APCmin/+ mice
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served as a control for baseline permeability. Error bars = SD, n = 5-6 per group for all
studies. Significance: *, **, *** denote p<0.05, 0.01, 0.001, respectively.
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Figure 7: IL-12 induces IFNγ and IL-10RA expression in the colon. (A) Quantitative
PCR analysis of IL-10RA and IFNγ mRNA. Quantitative PCR was performed to evaluate
relative changes in IL-10RA and IFNγ transcript levels in the colon in blank or cytokine
particle-treated mice. (B) IL-10RA expression on colon epithelium. Colon sections from
control (blank), IL-10, IL-12 and IL-10+IL-12-treated mice were stained for DAPI (blue),
E-cadherin (green), and IL-10RA (red) and visualized by laser-scanning confocal
microscopy. (C) FACS analysis of epithelial cell IL-10RA expression. Single cell
preparations from colon epithelia of control and treated mice (along with a negative
control, i.e. IL-10RA knockout wild-type B6 mice) were stained for EpCAM and IL-10RA
expression and were analyzed by flow cytometry. Representative panels and
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quantitative data are shown. Each circle indicates an individual mouse. Error bars =
SD. n = 5 per group. Significance: *, **, *** denote p<0.05, 0.01 and 0.001,
respectively.
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Figure 8: IFNγ and IL-10 jointly promote tight junction protein expression in the colon.
(A) Quantitative PCR analysis of IL-10RA, occludin and claudin-4 transcripts. Colon
explants were cultured for 24 hours in high glucose medium in the presence of
recombinant IL-10, IFNγ, or both as described in Materials and Methods. RNA was
extracted and IL-10RA, occludin and claudin-4 mRNA levels were quantified by qPCR.
Error bars = SD, n = 6 per group. (B) Analysis of protein levels. Protein was extracted
from colon explants cultured as above and analyzed by Western blotting to detect and
quantify IL-10RA, occludin and claudin-4. Representative blot displaying the bands for
each protein and β-actin (loading control) is shown. Signal intensity of each band was
normalized to β actin for loading in each lane and fold-change was calculated with
respect to untreated (control) explants. Combined data from two different blots are
shown. Error bars = SD, n = 5-6 per group. Significance: * denotes p<0.05.
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Figure 9: Hypothesized mechanism of action of IL-10 and IL-12 on colon epithelial
barrier integrity. IFN-γ produced by IL-12 activated T cells binds to IFNγR on the
basolateral surface of colon epithelial cells. Signaling through IFNγR results in
weakening of tight junctions and epithelial barrier integrity as well as increased
expression of IL-10R on the apical surface of colon epithelial cells. IL-10 binding to IL10R results in restoration of tight junctions and epithelial barrier integrity.
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CHAPTER FOUR
SAVING CHECKPOINT INHIBITORS
IDENTIFYING MECHANISMS OF RESISTANCE TO IMMUNE CHECKPOINT
INHIBITOR THERAPY IN COLORECTAL CANCER

Introduction
Over the last several years, the emergence of immune checkpoint inhibitors (ICIs),
particularly those targeted against PD-1/PD-L1, has heralded a significant shift in clinical
oncology.1-5 The therapeutic efficacy of these agents in melanoma and other solid
tumors (including lung, kidney, and head and neck cancer) has underscored the
powerful anti-tumor capacity of the immune system.6-11

Despite the success of anti-PD1 in the aforementioned malignancies, one notable area
in which such therapy has failed is in colon cancer.11,12 With the exception of tumors that
demonstrate significant microsatellite instability and a concomitant defect in mismatch
repair machinery, response rates to anti-PD1/PD-L1 therapy in colon cancer have
ranged from 0-5%.13,14 Currently, the mechanisms of resistance to anti-PD1 therapy in
such patients remain unclear. Given that patients in the latter category comprise
approximately 85-90% of all patients with colon cancer, understanding pathways
facilitating resistance and identifying potential therapeutic targets represents a significant
area of need in clinical oncology.15,16
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To date, the majority of studies evaluating mechanisms of resistance to anti-PD1/PD-L1
therapy have focused on melanoma given the significant role of such ICIs in treatment of
this disease. Various groups have demonstrated in both preclinical models and patient
samples the roles of differential gene transcription among different tumor foci, Jak1/2
mutations, loss of β2-microglobulin, and a number of other innate elements comprising
cytokines, chemokines, and proteins involved in angiogenesis, among other things.17-21
While these mechanisms of resistance are postulated to extend to other tumor types,
which, if any, actually do apply in the setting of other malignancies and whether or not
additional mechanisms may play critical roles in mediating resistance to ICIs remains
unclear.

Based on our findings demonstrating the importance of T17 cells to the persistence and
progression of colon tumors (see Chapter 3), we believed that IL-17 producing cells
could play a critical role in mediating resistance to anti-PD1 therapy in colon cancer. In
the present study, we sought to identify putative immunological mechanisms involved in
failure of oral anti-PD1 therapy in a preclinical model of colon cancer. The results
presented herein demonstrate the importance of IL-17 and γδ T cells in colon cancer’s
resistance to ICI therapy, thereby pointing toward possible combination therapy
strategies to improve ICI efficacy in treatment of colon cancer.

Materials and Methods
Mice and the tumor model. C57BL/6 (B6) and C57BL/6J-ApcMin/J (APCMin/+) mice were
purchased from Jackson Laboratory. Enterotoxic B fragilis strain 86-5443-2-2 was a kind
gift from Dr. Cynthia L Sears (Johns Hopkins University School of Medicine, Baltimore,
Maryland). For colonization with B fragilis, 5-6 week old APCMin+ mice were administered
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clindamycin (0.1g/L) and streptomycin (5g/L) ad libitum in drinking water for 5 days
before oral gavage (~5×107 bacteria in PBS) as previously described. All studies were
conducted in accordance with guidelines set forth by the Institutional Animal Care and
Use Committee at the University of Louisville (Louisville, KY).

Reagents and treatments. Two particle formulations were produced using a modified
Phase Inversion Nanoencapsulation (PIN) process: (i) control (no cytokine) and (ii)
murine anti-PD1 (Clone J43, BioXCell) with a loading of 1.0 μg antibody/mg of particles.
Particles were administered via oral gavage (2.5 mg particles in 0.2 mL sterile water for
blank and anti-PD1 treatments) starting 4 weeks after B fragilis inoculation three times
per week for 3 weeks.

Gross intestinal preparation and tumor quantification. Colons were opened longitudinally
before being fixed in 10% neutral buffered formalin. Tumor burden was quantified using
a dissecting microscope.

Histology. Formalin-fixed, paraffin-embedded tissue from the distal colon was sectioned
serially (5μm sections) and subsequently stained with Hematoxylin and Eosin (H&E).
Colon histology was assessed in a blinded fashion by a single tumor pathologist. Each
section was classified as harboring no dysplasia, low grade dysplasia, or high grade
dysplasia. Colons were then scored according to the following system based on the
average severity of dysplasia in the distal colon: 0 – no dysplasia; 1 – low grade
dysplasia only; 2 – mixture of low grade and high grade dysplasia; 3 – high grade
dysplasia only; 4 – invasive adenocarcinoma.
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Flow cytometry. Membrane and intracellular staining of MLN cells and lamina propria
lymphocytes (LPL) were performed as described.22 The following antibodies were used:
CD4 (GK1.5, BioLegend), CD8α (53-6.7, BD Biosciences), CD45.2 (104, BD
Biosciences), CD16/CD32 (93, BioLegend), γδTCR (GL3, BioLegend), IL-17A (TC1118H10.1, BioLegend), IFNγ (XMG1.2, BD Biosciences).

Lymphocyte depletion and functional blockade studies. Anti-mouse CD4 (GK1.5,
BioXCell) was given intraperitoneally (ip) to APCmin/+ mice (0.2mg, three times per week
for 3 weeks) to deplete CD4+ T lymphocytes. Anti-mouse γ/δ TCR (UC7-13D5, Leinco
Technologies) was given ip to APCmin/+ mice (0.25 mg, twice per week for 3 weeks) to
deplete γ/δ TCR+ T lymphocytes. Anti-mouse IL17 (17F3, BioXCell) was injected ip
(0.2mg, three times per week for 3 weeks). All treatments were initiated on treatment
day -1 (the day before receiving their first oral immunotherapy treatment) and again on
treatment day 0 (the day of their first oral immunotherapy treatment).

Statistical Analysis. Two-tailed student’s t-test was used to determine the significance of
the differences between control and experimental groups in pairwise comparisons. In
experiments with multiple groups homogeneity of inter-group variance was analyzed by
one-way ANOVA with Tukey’s honest standard difference for multiple comparisons. P
values less than 0.05 were considered statistically significant. Statistical analyses were
performed using GraphPad Prism 7 (GraphPad Software, La Jolla, California, USA) and
MedCalc version 17.9.7 (MedCalc Software, Ostend, Belgium).
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Results
Orally administered checkpoint inhibitor monotherapy is ineffective against colon cancer
Outside of cases with high microsatellite instability, previous work has demonstrated a
general lack of efficacy of immunotherapy in colon cancer. To evaluate whether orally
administered anti-PD1, which would augment local delivery of checkpoint inhibitor to the
colon, would result in effective treatment, mice were treated with either blank or antiPD1-containing particles by oral gavage for three weeks. No significant differences were
noted in tumor number, maximum tumor diameter, or histologic severity of disease
(Figures 1A, 1B). These findings confirmed failure of anti-PD1 monotherapy in treatment
of colon cancer, suggesting that simply altering the method of delivery could not
overcome therapeutic resistance.

IL-17 blockade significantly improves the efficacy of anti-PD1 therapy in treatment of
colon cancer.
IL-17 has been demonstrated to play a significant role in the development and
progression of colon cancer. Given the known tumor-promoting role of IL-17 in this
setting, we hypothesized that blockade of this signaling could result in a more favorable
immune microenvironment that could augment the efficacy of anti-PD1 treatment.
Towards this end, mice were subjected to IL-17 blockade and treated with either blank or
either anti-PD1 containing particles for 3 weeks. While IL-17 blockade significant
improved tumor number, compared to treatment with either blank or anti-PD1 particles
alone, the combination of IL-17 blockade and anti-PD1 treatment resulted not only in
near complete eradication of tumors, but also significant reductions in both maximum
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tumor diameter and histologic severity (Figure 2A-C). These findings indicate that IL-17
plays a critical role in mediating failure of anti-PD1 therapy in colon cancer.

Γδ TCR+ T cells, but not CD4+ T cells, play a critical role in IL-17 mediated resistance to
anti-PD1 therapy
As previously mentioned, several cell populations are known to produce IL-17.
However, as previously demonstrated, two subsets of T cells – γδ17 cells and CD4+
Th17 cells – play a critical role in promoting colon tumor development. To determine
which of these cell populations contributed to IL-17 production involved in anti-PD1
resistance, mice were subjected to either CD4+ T cell depletion or γδ TCR depletion in
the context of treatment with either blank or anti-PD1 particles. CD4+ T cell depletion
had no significant effect on either tumor number of maximum tumor diameter, either
alone or when combined with anti-PD1 therapy (Figure 4A, 4B). However, depletion of
γδ TCR+ T cells resulted in a significant reduction in tumor number but not maximum
tumor diameter (Figure 3A, 4B). These results suggest that γδ T cells may be major
mediators of anti-PD1 resistance in colon cancer in an IL-17 dependent manner.

Discussion
Clinical trials of ICI therapy, particularly with anti-PD1/PD-L1, have demonstrated
minimal, if any, effect in patients with microsatellite stable colon cancer. Despite several
mechanisms of resistance having been postulated, none have been conclusively shown
in either preclinical models or human subjects. Our results indicate that IL-17 represents
a critical element mediating anti-PD1/PD-L1 resistance in microsatellite stable colon
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cancer. Moreover, a large component of this IL-17 effect appears to derive from γδ T
cells in the tumor microenvironment.

The tumor-promoting effects of IL-17 in colon cancer have been demonstrated both in
preclinical models and IL-17’s role in colon cancer. IL-17 binds to its ubiquitouslyexpressed cognate receptor (IL17RA) to result in release of pro-inflammatory cytokines
and chemokines as well as increased expression of angiogenesis promoting factors (i.e.
VEGF, prostaglandin E1, prostaglandin E2). Indeed, IL-17 has been shown to promote
tumor growth and augment vascularity in murine models of colon cancer.23 Human
studies have also demonstrated an association of IL-17 mRNA with increasingly
dysplastic colon tumors along the adenoma to carcinoma pathway as well as increased
levels of IL-17 in colon cancer tissue, with the IL-17E subtype related to tumor cell
differentiation.24,25

In colon cancer, two cell subsets have been strongly linked with IL-17 production: Th17
cells and γδT17 cells. The role of Th17 cells in promoting colon tumorigenesis has been
previously demonstrated.26,27 However, recent evidence has suggested that IL-17
producing γδ T cells play a critical role in tumor progression. These cells, largely
expanded in the tumor microenvironment, have been shown to accumulate in colon
tumor tissue, potentially being polarized therein by cytokines (including dendritic cellproduced IL-23) present in the tumor microenvironment.28 This situation results from
weakened colothelial barrier integrity, bacterial translocation, and resultant attraction of
dendritic cells into peritumoral tissue.28 The end result of γδT17 activation and
proliferation is recruitment of PMN-type myeloid derived suppressor cells and
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subsequent immunosuppression.28 Taken together with our findings, these data
underscore the importance of γδT17 cells in supporting a microenvironment favoring
tumor growth in colon cancer.

In the context of previous work, our findings suggest that the relative importance of Th17
and γδT17 to promoting tumor development and growth may exhibit temporal variation.
As previously mentioned, Th17 cells have been shown to be important in colon
tumorigenesis, findings supported by work from our group demonstrating the abrogation
of tumor formation with CD4+ T cell depletion.22,26,27,29 In the setting of established
colon tumors, however, our data suggest that γδT17 cells appear to play a more critical
role in maintaining a tumor-promoting, immunosuppressive microenvironment. While
future work is required to elucidate the mechanisms underpinning this observation and
appropriately test the hypothesis of a time-dependent importance of Th17 and γδT17
cells in colon tumorigenesis and progression, the role of γδT17 cells later in disease may
stem from the changes in colon permeability, bacterial translocation, and DC recruitment
associated with increasingly dysplastic lesions.

Our findings have exciting implications for future applications in treatment of patients
with colon cancer. Both IL-17 and γδ T cells represent putative targets for therapies that
could be combined with anti-PD1/PD-L1 to augment the efficacy of the latter agent.
While no anti-γδ T cell antibody is currently approved for clinical use, an FDA-approved
anti-IL-17 antibody, secukinumab (Cosentyx; Novartis International AG, Basel,
Switzerland), is currently being used in treatment of patients with plaque psoriasis. With
a low side-effect profile (approximately 10% adverse event rate), combination of this
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agent with anti-PD1/PD-L1 represents an enticing possibility for future clinical trials in
patients with colon cancer.30

If successful, such combination therapy would represent

a significant advance in the treatment of colon cancer, providing patients and physicians
with a presumably well-tolerated, effective treatment regimen with application in a wide
variety of disease settings.

Conclusions
The results of these studies suggest that IL-17-producing γδ T cells play a critical role in
mediating resistance of colon tumors to anti-PD1 therapy. While the detailed
mechanisms underlying this observation remain areas for future study, the phenomena
described herein represent exciting possibilities for clinical trials combining existing antiIL-17 therapy with anti-PD-1 therapy in patients with microsatellite stable colon cancer,
anti-PD1 refractory microsatellite unstable colon cancer, and, potentially, other tumor
types with in which IL-17 plays a role in tumor development.
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Figure 1: Oral anti-PD1 monotherapy is ineffective in treatment of established colon
tumors. (A,B) Colon tumor number and maximum diameter. APCmin/+ mice were treated
with oral particle-based therapy (either blank particles or particles loaded with murine
anti-PD1 antibody) for 3 weeks beginning 4 weeks after enterotoxic B fragilis inoculation.
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Mice were then euthanized, and tumor number (A) and maximum tumor diameter (B) in
the mouse colon were assessed. Error bars = SD, n = 5 per group.
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Figure 2: IL-17 blockade significantly improves the efficacy of oral anti-PD1 in treatment
of established colon tumors. (A, B) Colon tumor number and maximum diameter.
APCmin/+ / B fragilis mice were treated with oral particle-based therapy (blank, anti-PD1)
for 3 weeks with and without IL-17 blockade by intraperitoneal injection of anti-IL-17A
monoclonal antibody. Mice were then euthanized, and tumor number (A) and maximum
tumor diameter (B) in the mouse colon were assessed. Error bars = SD, n = 6 per
group.
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Figure 3: IL-17-based resistance to anti-PD1 therapy appears mediated by γδTCR+ T
cells but not CD4+ T cells. (A, B) APCmin/+ / B fragilis mice were treated with oral
particle-based therapy (blank, anti-PD1) for 3 weeks with and without either CD4+ T cell
depletion or γδ T cell depletion by intraperitoneal injection of α-CD4 or α-γδ TCR
monoclonal antibody. Mice were then euthanized, and tumor number (A) and maximum
tumor diameter (B) in the mouse colon were assessed. Error bars = SD, n = 2-5 per
group.
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CHAPTER FIVE
THE NEXT FRONTIER
ESTABLISHING A PRACTICAL MODEL FOR SPONTANEOUS COLON TUMORS

Introduction

Among patients with colorectal cancer, approximately 10-25% initially present with liver
metastases.1 Moreover, even among patient who undergo successful resection of their
primary tumor, nearly 50% will ultimately develop liver metastases.1 While a solitary
liver metastasis or oligometastatic disease often responds well to systemic
chemotherapy and resection, the metastatic disease setting still represents the area in
which novel therapies are most sorely needed, particularly since chemotherapy
converts patients to resectability in 7-50% of cases.2 Thus, a practical, high-fidelity
preclinical model for colorectal liver metastases remains essential for the effective
evaluation of new therapeutic agents.

Currently, numerous models of colon cancer exist, ranging from those involving
chemical induction (1,2-dimethyhydrazine (DMH) and azoxymethane (AOM)) to a
combination of a germline mutation and bacterially-induced inflammation
(APCMin/enterotoxic Bacteroides fragilis) to genetically modified mice that allow for sitespecific induction of mutations commonly found in patients with colon cancer (e.g. Apc,
Kras, Msh2).3-6 While each has its own advantages and disadvantages, they all provide
reasonable model systems for assessing the development and progression of both
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sporadically arising colon tumors and those developing in the setting of chronic
inflammation (i.e. colitis). However, none of these models produce colon tumors that
spontaneously metastasize to the liver, thereby limiting their ability in assessing both the
process of metastasis development and the impact of antineoplastic agents on both
primary tumors and metastatic disease.7

To study colorectal liver metastases, researchers have largely had to rely upon
orthotopic injection of tumor cells (i.e. injection directly into the liver), implantation of
tumors into colons of nude mice, or injection of tumor cells into the portal vein to allow
diffuse seeding of the liver.4,8-10 Unfortunately, none of these models accurately reflects
the clinical setting in which such disease develops. In order to address the need for a
more clinically-relevant model of colorectal liver metastases (and colon cancer in
general), KE Hung and colleagues developed a model utilizing site-specific, inducible
mutations in Apc and Kras that reliably resulted in formation of one to two colon tumors
that progress along the adenoma to carcinoma sequence and progresses to liver
metastases in approximately 20% of mice.7

Use of this model, while high-fidelity, has not been reported in any studies since its
publication. Several reasons likely explain this observation. First, the model requires a
significant amount of technical expertise due to multiple surgical elements (laparotomy,
colostomy, and surgical repair of both incisions). Additionally, the procedure is quite
inefficient and time intensive, with only 50% of mice developing carcinomas at 20 weeks
after tumor induction and metastases developing in only 20% of mice 24 weeks after
tumor induction.7 Thus, the model, while clinically relevant, remains largely impractical
for laboratory use.
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Given the well-described use of mouse colonoscopy, we believed that using endoscopic
methods would allow us to circumvent several of the technical complexities associated
with this model.11,12 Additionally, such methods would allow for targeted mutation at a
specific site in the distal colon which could be easily and reliably monitored for tumor
development and progression. Herein, we describe a minimally-invasive endoscopic
methods for induction of Apc and Kras mutations resulting in distal colon
adenocarcinoma development in addition to eventual development of gross liver
metastases.

Methods
Animals
Apc conditional knockout mice (C57BL/6-Apctm1Tyj/J, Jackson Labs) were crossed
with mice bearing a latent mutant Kras allele (LSL-K-ras G12D, Jackson Labs). Mice
had Apc and Kras mutations, respectively, under control of an LSL system, with
mutation inducible by insertion of a Cre recombinase-expressing adenovirus. Breeding
consisted of a C57BL/6-Apctm1Tyj/J male crossed with a LSL-K-ras G12D female.
Progeny were genotyped using the methods described by Jackson Labs. Progeny
positive for both latent Apc and Kras alleles were utilized for experimentation.

Mouse Colonoscopy and Adenovirus Infection of Colon Epithelium
Mice were anesthetized using ketamine/xylazine anesthesia. After achieving an
adequate level of anesthesia an 8F pediatric cystoscope was introduced into the mouse
anus and advanced proximally approximately 2-3 cm. Air was insufflated during this
time to allow for adequate visualization while avoiding perforation. The colon was then
flushed with 300 mL 1x PBS, and 200 mL 0.25% trypsin with EDTA was instilled via the
working port of the colonoscopy while slowly withdrawing the instrument. Mice were
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positioned with their head down for 15 minutes to allow for trypsin digest of intercellular
adhesion molecules between colon epithelial cells. The colonoscopy was subsequently
reinserted and biopsy forceps were used to create a discrete break in the epithelium of
the distal colon under direct visualization. Care was taken to avoid taking a fullthickness biopsy and causing a colon perforation. To induce gene mutation at the site
of the biopsy, 109 PFU of Ad5CMVcre High Titer (HT) (Viral Vector Core, University of
Iowa) in 50 μL of 1x PBS were injected into the muscularis mucosa using a microneedle
inserted through the colonoscopy working port under direct visualization. Care was
taken not to allow transcolonic needle penetration with viral instillation into the
peritoneal cavity. After instillation, the needle was withdrawn into the working port, and
the colonoscope was withdrawn slowly. Mice were observed in cages placed on a 37°C
heating pad until they began moving spontaneously.

Monitoring Tumor Development
To monitor for tumor development and progression, mice underwent serial biweekly
colonoscopy as described above beginning two weeks after virus instillation.
Adenomas were biopsied using biopsy forceps inserted through the working port of the
colonoscope. Biopsies were placed in 10% neutral buffered formalin for histologic
analysis. Mice were then euthanized at two week intervals beginning six weeks after
adenoma formation to assess time to adenoma formation and time from adenoma
formation to carcinoma development. At time of euthanasia, colons were excised,
bisected longitudinally, and rinsed with 1x PBS to remove stool and mucous before
being placed in 10% neutral buffered formalin. Colons were embedded in paraffin and
sectioned at 10 μm intervals before being stained with hematoxylin and eosin (H&E) for
pathology analysis.
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Assessing for Metastasis Development
To determine time to metastasis development, mice were euthanized beginning 12
weeks after virus instillation. Colon, mesenteric lymph nodes (MLN), and liver were
excised. Colons were treated as described above, and all organs were placed in 10%
neutral buffered formalin. Organs were embedded in paraffin and sectioned at 10 μm
intervals before being stained with hematoxylin and eosin (H&E) for pathology analysis.

Histologic Analysis
H&E stained slides were reviewed by an experienced colorectal pathologist to
determine the presence of adenoma, carcinoma, and metastatic disease (in the lymph
nodes and liver). Descriptive analysis was provided in addition to classification of
lesions as adenoma or carcinoma.

Results
Endoscopic adenovirus instillation is feasible and safe
As previously mentioned, we initially sought to determine whether we could employ
endoscopic methods to improve the feasibility of the model previous described by Hung,
et al.7 The apparatus and setup used are depicted in Figure 1. For optimal execution,
the procedure was noted to require two operators: one for operation of the biopsy
forceps and microneedle and one for manipulation of the colonoscope. This system
enabled successful creation of a mucosal break and adenovirus injection in 20 of 22
mice (91%) on five separate occasions. Mice tolerated the procedure well; only two
mice developed colon perforations and required euthanasia.
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Endoscopic adenovirus instillation results in adenoma formation 2-3 weeks after
mutation induction
To evaluate whether endoscopic adenovirus instillation reliably resulted in tumor
formation and the time to initial adenoma formation, mice underwent colonoscopy every
two weeks beginning two weeks after adenovirus instillation. Adenoma formation was
noted at two weeks after adenovirus injection (Figure 2A). Time to adenoma formation
was similar in five mice injected with adenovirus. Histologic analysis of biopsies
obtained from the lesions confirmed development of adenomas (Figure 2B).

Histologic analysis demonstrates adenoma to carcinoma transition at 12 weeks after
adenovirus injection
To assess the time from adenoma formation to the development of invasive carcinoma,
three mice were euthanized at 12 weeks after adenovirus injection (10 weeks after
adenoma development). Histologic analysis of the tumors demonstrated invasive
carcinoma (Figure 3A). Histologic evaluation of the liver at this time demonstrated no
evidence of metastatic tumor deposits (Figure 3B).

Spontaneous development of liver metastases
For evaluation of time to development of lymph node and/or liver metastases, mice were
sequentially euthanized beginning at 20 weeks after adenovirus injection. Histologic
analysis did not demonstrate any evidence of microscopic disease in either mesenteric
lymph nodes or colon until 48 weeks of age. One of three mice euthanized at this time
was noted to have gross evidence of widespread liver metastases (Figure 4).

98

Discussion
As previously mentioned, current models of colorectal cancer in general and liver
metastases in particular fail to accurately reflect the most prevalent clinical scenario of
spontaneous arising colon tumors (adenomatous polyps) that eventually transition to
carcinoma and, in certain cases, to colorectal liver metastases.4,13 Despite the
development of a model that successfully recapitulates this scenario, its technical and
logistic impracticality has limited its use. The model described herein overcomes many
of those obstacles and represents a significant practical improvement on the
aforementioned system.

The method we describe likely works reliably and efficiently for several reasons. Using
biopsy forceps to create a discrete mucosal break through which to perform submucosal
adenovirus instillation allows for several key elements: 1) a tumor confined to a known,
specific region in the distal colon, 2) the ability to administer a high concentration of virus
in a small volume to a naturally confined region, avoiding the need to segmental colon
occlusion and incubation, and 3) improved adenovirus penetration into cells with
transformation potential (i.e. cells other than well-differentiated epithelial cells),
maximizing transformation efficiency. Furthermore, by utilizing colonoscopy for
instillation, our method not only allows for visual confirmation of successful injection, but
also facilitates stool clearance. As previously mentioned, such an approach also spares
mice the morbidity of a laparotomy and colostomy and, as a result, decreases the time
mice must be under general anesthesia.
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As previously discussed, the value of a high-fidelity model for colon cancer and
colorectal liver metastases cannot be overstated. Such a model would enable more
granular, detailed analysis of the genetic, molecular, and immunologic elements
associated with and responsible for the adenoma to carcinoma transition and the
development of liver metastases. Additionally, it would allow for realistic evaluation of
the performance of novel imaging modalities (i.e. multispectral optoacoustic tomography
(MSOT)) along with tracers and dyes in conjunction with existing modalities (i.e.
magnetic resonance imaging (MRI), computed tomography (CT), or high-resolution
ultrasound (U/S)) in early detection of primary colon tumors and liver metastases.
Finally, such a model represents a significant improvement over those currently
available for evaluation of the therapeutic potential of novel cytotoxic and immune-based
therapies along the spectrum of colorectal cancer.

Despite the findings presented herein, several aspects of this model system require
further investigation. The exact time at which mice develop microscopic liver
metastases remains unclear, as does the proportion of mice who develop hepatic
metastases. Accurately elucidating these elements will likely require a large, longitudinal
study employing a combination of colonoscopy and sequential non-invasive liver imaging
using high-resolution ultrasound and euthanasia. Furthermore, the degree to which this
model reflects the known mutational and methylation profiles of human colon adenomas,
carcinomas, and liver metastases remains unknown. Targeted or whole genome
analysis of tumor tissue from a large cohort of mice could help delineate the degree to
which this model parallels human colon cancer on a genetic and epigenetic level.
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Conclusions
The results described herein demonstrate that a colonoscopy-based virus delivery to a
site of mucosal disruption in mice with inducible Apc and Kras mutations represents a
feasible, safe, and effective method of inducing spontaneous colon tumors that
demonstrate a stepwise progression along the adenoma-carcinoma-metastasis pathway.
Such a model enables evaluation of study of the genetic and immunologic perturbations
both locally and systemically throughout this process. Furthermore, it provides an
extremely clinically-relevant system for evaluation of the therapeutic efficacy of novel
antineoplastic agents as well as imaging modalities for detecting sub-clinical disease.
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Figures

A.

B.

102

C.

D.
Figure 1: Mouse colonoscopy and adenovirus instillation. (A) Complete setup for
mouse colonoscopy, including colonoscope, colonoscope holder, and microneedle.
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(B, C) Biopsy forceps grasping tissue (B) and mucosal break following tissue biopsy
(C). (D) Microneedle inserted into mucosa for adenovirus delivery.
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A.

B.
Figure 2: Gross and histologic demonstration of colon adenoma formation. (A)
Endoscopic visualization of colon adenoma two weeks after adenovirus instillation.
Black arrows indicate polyps. (B) Histology of colon tumor biopsy (4x) demonstrating
hyperplasia and mild architectural distortion consistent with a colon adenoma.
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A.

B.
Figure 3: Histologic evaluation of colon tumor, mesenteric lymph nodes, and liver 12
weeks after adenovirus instillation. (A) Histology of colon tumor (4x) demonstrates
invasive adenocarcinoma. (B) Representative histology of the liver (4x) showing no
evidence of metastases.
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A.
Figure 4: Gross demonstration of colorectal liver metastases 48 weeks after adenovirus
instillation.
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OVERALL SUMMARY AND FUTURE DIRECTIONS

This dissertation began with an investigation into colon inflammation, demonstrating not
only its severity in our main model system, but also the ability of a novel, non-invasive
imaging modality to identify areas of inflammation in the mouse colon. These findings
provided support for application of such technology in evaluation of human subjects at
risk for inflammatory bowel disease and colon cancer. The dissertation proceeded to
utilize that same imaging technology, together with fluorescence microscopy, to track
orally-administered particles. These studies allowed identification of sites of uptake of
these particles as well as delineating of the time course of uptake, trafficking, and
degradation. These particles were then used as mechanisms of cytokine delivery for
oral treatment of colon cancer. Combining oral IL-10 and IL-12 resulted in significant
decrease in tumor burden and histologic severity of disease as a result of modulation of
CD8+ T cells, RORγT+ IL-17 producing cells, and, most interestingly, colon membrane
permeability. Using the same model and drug delivery system, the dissertation
proceeded to demonstrate that IL-17 and γδ T cells mediate resistance of colon cancer
to anti-PD1 therapy, providing exciting potentials for targeted clinical investigation. The
dissertation concluded with description of a feasible preclinical model of spontaneously
developing colorectal liver metastases for the evaluation of genetic and immunologic
changes associated with development and progression of colon tumors as well as the
therapeutic effect of antineoplastic agents in the treatment of metastatic disease.
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Taken together, this body of work incorporates novel technologies, spans a wide range
of biologic investigations, offers potential solutions to significant clinical and preclinical
problems, and offers exciting opportunities for future lines of investigation. Indeed, as
mentioned herein, clinical trials involving MSOT for detection of colon cancer and
inflammatory bowel disease, and orally-delivered biodegradable particle-based therapy
and combination immunotherapy with anti-IL-17 and anti-PD1/PD-L1 are all imminently
realizable in the near future. These, together with opportunities for future studies
utilizing the C57BL/6-Apctm1Tyj/J x LSL-K-ras G12D adenovirus-based model, have the
potential to significantly impact diagnosis and treatment of colon cancer across all
stages of disease, thereby improving quality of life and oncologic outcomes for millions
of patients.
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Appendix 1: APCmin Genotyping Protocol
1. Make a master mix of 150 μL tail lysis buffer (Viagen DirectPCR (Tail), cat# 102T) per tail + 7.5 μL proteinase K (20 mg/mL) per tail.
2. Add 150 μL master mix to a 1.5 mL Eppendorf tube containing each tail snip.
3. Digest in hybridization oven under constant rotation for 1 hour at 57°C, vigorously
shaking tubes halfway through digestion.
4. Inactivate proteinase K by placing tubes in 95°C water bath for 1 hour.
5. Create PCR master mix as follows:
a. Promega Go Taq Green 2x (6.75 μL per tail)
b. Notch1-F (5 μM) (0.38 μL per tail)
c. Notch1-R2 (5 μM) (0.38 μL per tail)
d. APC-M-C (5 μM) (1.3 μL per tail)
e. APC-M-M (5 μM) (1.3 μL per tail)
f.

25 mM MgCl2 (0.4 μL per tail)

6. Add a total of 10.5 μL of master mix to each well.
7. Add 2.5 μL of DNA to each well (one tail per well).
8. Run PCR as follows:
a. Step 1: 94°C x 10 minutes
b. Step 2: 94°C x 30 seconds (x33)
c. Step 3: 53°C x 55 seconds
d. Step 4: 72°C x 1 minute
e. Step 5: 72°C x 2 minutes
f.

4°C x ∞

9. After PCR complete, pour 3% agarose gel
a. Mix 3 g agarose with 150 μL 1x TBE buffer in a graduated cylinder
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b. Microwave for 2 minutes or until all agarose is dissolved and mixture is
clear and boiling.
c. Add 2.5 μL ethidium bromide to solution.
d. Pour into gel box.
e. Let cool completely (approximately 1 hour).
10. Load DNA ladder, negative control, positive control, tail samples into discrete
wells.
11. Run gel at 150V for 40 minutes or until adequate band separation occurs.
12. Image gel using ultraviolet transilluminator, 302 nm.
13. Compare to representative image below to differentiate APCmin/- from APCmin/+
mice.
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Appendix 2: Enterotoxic Bacteroides fragilis (serotype 086) Growth Protocol

Preparing B. fragilis strain (086-ETBF) for inoculation
1.

The B. fragilis strains should be first brought up from the stock (usually stored in

30% glycerol at -80ºC) by picking one loop of the stock using sterilized inoculation loop
and streaking on pre-made BHI/Clindamycin agar plates . The inoculation agar plates
then should be incubated at 37ºC in an anaerobic condition for 2 days.
2.

After the 2 days’ incubation, take the agar plate out and exam the growth and the

purity of bacteria. Pick a couple of colonies with pipette tip, swirl into a culture tube with
5ml of BHI/Clindamycin broth. Cap the tube loosely and incubate at same condition as
the agar plate above for 24-48 hours.
3.

Prepare a new tube with 10ml of BHI/Clindamycin broth and sub-grow the

bacteria
for 24 hours from the previous broth culture at a ratio of 1:100 dilution (inoculation 100 µl
of culture into 10ml of BHI broth).
4.

After overnight incubation, the bacteria should grow well (the broth turn from

clear to
cloudy). Spin down bacteria (10,000rpm for 2 minutes), and wash the bacteria pellet
twice with 1x PBS. Re-suspend into 1x PBS at 80% of the original volume, then adjust
the OD600 = 0.6-0.8.

BHI Agar plates w/Hemin, Vitamin K, Clindamycin

For 1 liter:

BHI: 37g/L (BD Bacto™ BHI, REF 237200)
141

Yeast Extract: 5g/L (BD Bacto™, REF 212750)
L- Cysteine: 0.5g/L (Sigma C7352)
Agar: 15g/L (BD Bacto™, REF 214010)

•

Combine ingredients in autoclavable container, add water to final volume of 1L



Autoclave (sterilization time should be 30 minutes)

•

Let broth cool down to room temperature, about 45 minutes

•

Add:
Hemin solution: 10ml/L (Sigma H5533)
Vitamin K: 0.2ml/L (Sigma V3501)
Clindamycin: 6µg/mL

•

Mix well by swirling the bottle. Do not shake the bottle (it will generate lots of

bubbles)
•

Pour plates; after BHI/Agar solution solidified, turn plates upside down, store
plates in plastic bag at 4°C.

Liquid BHI broth

BHI: 37g/L
Yeast Extract: 5g/L
L- Cysteine: 0.5g/L

•

Combine ingredients in autoclavable container, add water to final volume of 1L



Autoclave

•

Let broth cool to room temperature

•

Add:
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Hemin solution: 10ml/L
Vitamin K: 0.2ml/L
Clindamycin: 6µg/mL


Mix the solution

•

Filter the broth, make aliquots, store at 4°C covered in silver foil.

Hemin solution

For 100ml:



Weigh 50mg hemin in a weighing boat



Add 1 ml of 1N NaOH directly on the weighing boat, let it dissolve



Add some dH2O



Pour hemin solution into a 100ml bottle and add water to bring the volume to 100
mL.



Autoclave



Store at 4°C covered in silver foil.

Vitamin K1 solution



Dissolve 0.15 ml of Vitamin K1 in 30ml of 95% ethanol



Filter



Store Vitamin K1 stock solution at 4°C in brown bottle or wrapped with aluminum foil.
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Appendix 3: Enterotoxic Bacteroides fragilis (serotype 086) Inoculation Protocol
1. Ensure mice are approximately 5 weeks of age. Younger mice will have a high
mortality rate. In older mice, bacteria will be less effective at eliciting
tumorigenesis.
2. 5 days prior to planned inoculation, place mice on water containing clindamycin
(0.1 g/L) and streptomycin (5 g/L). Mice will take this water ad libitum until the
day of inoculation.
3. On day of inoculation, place mice on standard water. Failure to do so will result
in bacterial eradication after inoculation.
4. Using a 24 gauge feeding needle, administer 200 μL ETBF suspension by oral
gavage.
5. Inject each mouse with 500 μL lactated ringers or normal saline intraperitoneally
using a 26-30 gauge needle.
a. Mice suffer from dehydration as a result of the diarrhea that bacterial
inoculation induces. IP fluid administration beginning on the day of ETBF
inoculation helps prevent severe dehydration and decreases mouse
mortality.
6. Monitor the mice daily for at least 7 days after bacterial inoculation. Administer
500 μL lactated ringers or normal saline intraperitoneally as described in (5)
throughout this time period.
7. For evaluation of early disease, begin treatment 7-10 days after ETBF
inoculation. For evaluation of later stage disease, begin treatment 4 weeks after
ETBF inoculation.
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Appendix 4: Lymphocyte Isolation and Staining for Flow Cytometry Analysis
Protocol
Reagents
 Pre-digestion Buffer
o

500 mL 1x PBS

o

1 mM DTT (MW = 154.2, 1 mM = 0.077g in 500 mL)

o

10 mM EDTA (MW = 372.2, 10 mM = 1.861g in 500 mL)

 Digestion Buffer (PREPARE FRESH PRIOR TO EACH USE)
o

95 mL RPMI 1640

o

5 mL FBS

o

0.10 g Collagenase (Roche)

 Cell culture medium
o

500 mL RPMI 1640

o

5% FBS

o

100 U/mL penicillin (50000 U/500 mL)

o

100 U/mL streptomycin (50000 U/500 mL)

 2% FBS-PBS
 90% Percoll (to be used in making 67%, 44% Percoll solutions)
o

90 mL Percoll

o

10 mL 10x PBS

 67% Percoll
o

74.4 mL 90% Percoll

o

25.6 mL cell culture medium

 44% Percoll
o

48.9 mL 90% Percoll
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o

51.1 mL cell culture medium

 FoxP3 Wash Buffer
o

5 mL FoxP3 wash buffer concentrate

o

45 mL ddH20

 Sample Fixing Buffer
o

250 microliters fixing buffer concentrate

o

750 microliters fixing buffer diluent

 EC/IC Stain Master Mix
o

10 microliters FoxP3 wash buffer per sample

o

0.325-1.00 microliters fluorophore-labeled antibody per sample

Procedure
1. Place Pre-digestion Buffer and Digestion Buffer in water bath at 37°C
approximately 30 minutes prior to starting procedure.
2. Prepare ice tray for working with colon.
3. Sac mice, resect colon, mesenteric LN. Take care to remove excess mesenteric
tissue from colon specimen, MLN.
4. Place MLN in 7-8 cc cell culture medium.
5. Lavage colon with ice cold PBS via plastic-tipped feeding needle to evacuate
stool.
6. Hemisect colon longitudinally.
7. Place in petri dish with ice-cold PBS, wash vigorously for 10 seconds.
8. Morcellate very finely using scissors. Pieces should be between 0.2-0.5 mm in
maximal diameter.
9. Place colon in 15 mL Pre-digestion Buffer.
10. Incubate colon at 37°C for 30 minutes in hybridization oven under slow rotation.
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For MLN Processing
11. Decant MLN + medium into small petri dish. Homogenize MLN between two
frosted microscope slides.
12. Use 5 mL pipette to transfer cell suspension back to 15 mL centrifuge tube.
13. Spin 400xg, 4°C, 5 min
14. Decant supernatant, resuspend with 10 mL media.
15. Transfer suspension into 50 mL centrifuge tube with 40 micron filter (green).
Keep at 4C.
For Colon Processing and LPL Isolation
16. Decant colon after incubation into labelled 50 mL centrifuge tube with 100 micron
filter (yellow).
17. Add 10 mL room temperature 1x PBS to original centrifuge tube, decant into
tube with filter.
18. Scrape tissue atop filter into original centrifuge tube, add 15 mL Digestion Buffer.
Return to hybridization oven, incubate at 37°C for 30 minutes under slow
rotation.
a. Note: This is a time-critical step. Not enough time will result in
inadequate connective tissue digestion and poor LPL yield. Too much
time will result in decreased cell viability.
19. After incubation, vortex each tube vigorously for 20 seconds.
a. Note: Vortexing for the full amount of time is critical to ensure
connective tissue dissociation and liberation of LPL.
20. After vortexing, decant digested colon into labelled 50 mL centrifuge tube with
100 micron filter (yellow).
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21. Rub any remaining pieces of colon in the 100 micron filter gently to mechanically
break up any residual connective tissue.
22. Add 10 mL cell culture medium to original 50 mL tube (the one in which the colon
was digested), swirl, and decant into tube with 100 micron filter. This will collect
any cells remaining in the tube/filter.
23. Centrifuge LPL samples at 400xg, 4°C, 5 min.
24. Discard supernatant and resuspend pellet in 10 mL cell culture medium. Decant
into 50 mL centrifuge tube with 40 micron filter (green).
25. Centrifuge LPL samples at 400xg, 4°C, 5 min.
26. Discard supernatant. Resuspend pellet in 8 mL 44% Percoll (room
temperature) and pipette cell suspension into 15 mL centrifuge tube.
27. Place glass Pasteur pipette (1 mL) in each centrifuge tube.
28. Slowly pipette 5 mL 67% Percoll (room temperature) into each Pasteur pipette
to underlay the 67% Percoll under the cell suspension (cells + 44% Percoll). Be
careful not to disturb sample and density gradient.
29. Centrifuge at 600xg, 22°C, 20 mins. Make sure Accel = SLOW, Decel = OFF.
30. After slow spin, aspirate off supernatant above cell layer using transfer pipette.
Get within 2 mL of cell layer (buffy coat) to remove as much fat and debris as
possible.
31. Pipette cell layer (about 1-1.5 mL) into 10 mL cell culture in 15 mL centrifuge
tube.
Cell Stimulation
32. Centrifuge at 400 x g, 4°C, 5 mins for LPL, MLN. Discard supernatant and
resuspend pellet in 2 mL cell culture medium for LPL, 10 mL cell culture medium
for MLN.
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33. Count cells for each sample. Adjust cell concentration to 1-2 million per mL.
34. Add BFA (5 microliters per mL), PMA (0.5 microliters per mL), ionomycin (0.7
microliters per mL), incubate at 37°C for 4-5 hours.
Staining for FACS Analysis
35. After incubation, transfer samples to labeled flow tubes. Spin at 400xg, 3 mins,
4°C.
36. Resuspend in 100 microliters cell culture medium. Add 0.7 microliters blocker
(CD16/32) to each tube, incubate at room temperature x 8 mins.
37. Make extracellular stain master mix
38. Add 10 microliters master mix per sample of EC stain master mix, incubate at
room temperature x 12 minutes
39. Centrifuge at 400 x g, 4°C, 3 min.
40. Resuspend in 2 mL 2% FBS/PBS, centrifuge
41. Resuspend in 300 microliters per sample fixing buffer, incubate at 4°C x 30 mins
42. Add 700 microliters FoxP3 wash buffer, centrifuge 1500 RPM, 4°C, 3 min
43. Make intracellular stain master mix
44. Resuspend in 50 microliters FoxP3 wash buffer. Add 10 microliters IC master
mix per sample. Incubate overnight at 4°C.
45. Add 700 microliters FoxP3 wash buffer, centrifuge 1500 RPM, 4°C, 3 min
46. Reconstitute in 400 microliters FoxP3 wash buffer, ready for FACS analysis.
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Appendix 5: APCCKO (C57BL/6-Apctm1Tyj/J) Genotyping Protocol
1. Make a master mix of 150 μL tail lysis buffer (Viagen DirectPCR (Tail), cat# 102T) per tail + 7.5 μL proteinase K (20 mg/mL) per tail.
2. Add 150 μL master mix to a 1.5 mL Eppendorf tube containing each tail snip.
3. Digest in hybridization oven under constant rotation for 1 hour at 57°C, vigorously
shaking tubes halfway through digestion.
4. Inactivate proteinase K by placing tubes in 95°C water bath for 1 hour.
5. Create PCR master mix as follows:
a. Promega Go Taq Green 2x (6.25 μL per tail)
b. Primer 1 (WT Fwd 01MR) (5 μM) (1 μL per tail)
c. Primer 2 (WT Rev 01MR) (5 μM) (1 μL per tail)
d. ddH2O (2.25 μL per tail)
6. Add a total of 10.5 μL of master mix to each well.
7. Add 2.5 μL of DNA to each well (one tail per well).
8. Run PCR as follows:
a. Step 1: 94°C x 2 minutes
b. Step 2: 94°C x 25 seconds
c. Step 3: 65°C x 20 seconds
d. Step 4: 68°C x 15 seconds
e. Repeat Steps 2-4 x 10 (11 cycles total)
f.

Step 5: 94°C x 20 seconds

g. Step 6: 50°C x 20 seconds
h. Repeat Steps 5 and 6 x 25 (26 cycles total)
i.

4°C x ∞

9. After PCR complete, place samples in -20°C overnight.
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10. The next morning, pour 3% agarose gel
a. Mix 3 g agarose with 150 μL 1x TBE buffer in a graduated cylinder
b. Microwave for 2 minutes or until all agarose is dissolved and mixture is
clear and boiling.
c. Add 2.5 μL ethidium bromide to solution.
d. Pour into gel box.
e. Let cool completely (approximately 1 hour).
11. Load DNA ladder, negative control, positive control, tail samples into discrete
wells.
12. Run gel at 150V for 40 minutes or until adequate band separation occurs.
13. Image gel using ultraviolet transilluminator, 302 nm.
14. Compare to representative image below to differentiate negative from positive
mice.
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Appendix 6: LSL-K-ras G12D (B6.129S4-Krastm4Tyj/J) Genotyping Protocol
1. Make a master mix of 150 μL tail lysis buffer (Viagen DirectPCR (Tail), cat# 102T) per tail + 7.5 μL proteinase K (20 mg/mL) per tail.
2. Add 150 μL master mix to a 1.5 mL Eppendorf tube containing each tail snip.
3. Digest in hybridization oven under constant rotation for 1 hour at 57°C, vigorously
shaking tubes halfway through digestion.
4. Inactivate proteinase K by placing tubes in 95°C water bath for 1 hour.
5. Create PCR master mix as follows:
a. Promega Go Taq Green 2x (7.5 μL per tail)
b. Primer 1 (WT Fwd) (5 μM) (1 μL per tail)
c. Primer 2 (Mu Fwd) (5 μM) (1 μL per tail)
d. Primer 3 (Comm) (5 μM) (1 μL per tail)
e. ddH2O (2.5 μL per tail)
6. Add a total of 13.0 μL of master mix to each well.
7. Add 2.0 μL of DNA to each well (one tail per well).
8. Run PCR as follows:
a. Step 1: 94°C x 2 minutes
b. Step 2: 94°C x 20
c. Step 3: 65°C x 15 seconds
d. Step 4: 68°C x 10 seconds
e. Repeat Steps 2-4 x 9 (10 cycles total)
f.

Step 5: 94°C x 15 seconds

g. Step 6: 60°C x 15 seconds
h. Repeat Steps 5 and 6 x 27 (28 cycles total)
i.

4°C x ∞
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9. After PCR complete, pour 3% agarose gel
a. Mix 3 g agarose with 150 μL 1x TBE buffer in a graduated cylinder
b. Microwave for 2 minutes or until all agarose is dissolved and mixture is
clear and boiling.
c. Add 2.5 μL ethidium bromide to solution.
d. Pour into gel box.
e. Let cool completely (approximately 1 hour).
10. Load DNA ladder, negative control, positive control, tail samples into discrete
wells.
11. Run gel at 150V for 40 minutes or until adequate band separation occurs.
12. Image gel using ultraviolet transilluminator, 302 nm.
13. Compare to representative image below to differentiate negative from positive
mice.
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